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Summary 
 
2-dimensional gel electrophoresis (2-DE) is currently the method of choice for 
separation of complex protein mixtures such as in cell and tissue extracts or body 
fluids including urine or serum. Human urine plays a central role in clinical 
diagnostics of diseases such as cancer and inflammation. Researchers and 
scientists are working on the development of a map of the human proteome but in 
the literature there are only a few investigations about urinary proteomics and their 
behaviour in the case of bladder tumor. The first aim of this study was to view the 
whole proteins present in urine and to predict their functions. For this aim, fourtyfive 
urine samples from patients with bladder cancer of different stages, patients on 
follow-up and healthy volunteers were analysed by 2-DE. At the beginning of this 
study the 2-DE protein pattern of human urine was almost unknown because of lack 
of appropriate preparation of urine samples prior to the 2-DE. Thus, the study 
focused on methods for preparation of urine samples providing the best preservation 
of urinary proteins. After experimental optimization of 2-DE, usable 2-D protein 
patterns of urine were analysed to identify proteins related to bladder cancer using 
subsequent mass spectrometric analyses and/or conventional immunoblotting and 
immunohistochemical methods. In comparison to other cancer types, the bladder 
carcinoma is the seventh causing death in man and ninth in women among malignant 
tumors. The growth and metastasis as well as the transformation of superficial non-
invasive tumors to an invasive tumor phenotype are closely associated with 
activation of angiogenesis resulting in neovascularisation of tumor tissue. This 
process is regulated by a net balance between angiogenic activators and inhibitors. 
In the present study, orosomucoid (ORM) and human zinc-alpha-2-glycoprotein 
(ZAG) have been identified to be increased in 2-DE of urine samples of patients with 
bladder cancer in comparison to the urine samples of healthy volunteers. 
Immunohistochemical results let assume that in addition to cancer cells also a part of 
the tissue resident inflammatory cells and endothelial cells of tumor associated blood 
vessels may serve as source for this increase of ORM in urine samples of patient 
with bladder cancer. ORM is an acute phase protein and increased in acute infection, 
inflammation, and cancer. Recent studies show that ORM forms a complex with the 
active form of plasminogen activator inhibitor-1 (PAI-1) in thymosin β4 (Tβ4)-
activated but not in quiescent endothelial cells. Therefore it was aimed to determine a 
potential role of ORM up-regulation in angiogenesis. The findings presented in this 
Summary IX
study and results reported by Sorensson showed, that, in addition to the cancer cells, 
human vascular endothelial cells (HDMECs) produce ORM endogenously. For 
functional characterization of ORM in vascular endothelial cells, ORM-gene 
overexpression and ORM-gene silencing were perfromed. Employing the 
supernatants of HDMECs-ORM and HDMECs-ORM-siRNA in in-vitro angiogenesis 
assays, it was found that ORM supports the VEGF-induced endothelial tube 
formation. This supportive effect of ORM was potentiated by co-treatment of 
HDMECs with VEGF, ORM and anti-PAI-1 antibody. 
This study demonstrates for the first time that ORM is increased in urine of patients 
with bladder cancer and acts pro-angiogenic supporting the tube forming effects of 
VEGF. This supportative effect was significantly increased by additive blockage of 
PAI-1. 
In summary, the interaction between ORM and PAI-1 and anti-PAI-1 system seems 
to be essentially involved in the VEGF-mediated angiogenesis and probably in the 
vascularisation of urinary bladder cancer. 
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Zusammenfassung 
 
Bei der 2D-Elektrophorese (2-DE) handelt es sich zurzeit um die Methode der Wahl 
für die Trennung komplexer Proteinzusammensetzungen von Zell- und 
Gewebeextrakten sowie Körperflüssigkeiten wie Urin oder Serum. Die Untersuchung 
von Urinproben stellt eine zentrale Rolle in der Diagnostik von Krankheiten wie Krebs 
und Entzündungen dar. Wissenschaftler arbeiten an der Entwicklung eines humanen 
Gesamtproteomenmusters, in der Literatur sind jedoch nur wenige Untersuchungen 
zu Urinproteomics und ihrem Muster beim Harnblasenkarzinom beschrieben. Die 
Zielsetzung dieser Arbeit war die Untersuchung des Proteinmusters im Urin von 
Harnblasenkarzinompatienten im Vergleich zu normalen Patienten. Dazu wurden 45 
Urinproben von Harnblasenkarzinompatienten, Follow-up-Patienten und gesunden 
Probanden mittels der 2D-Elektrophorese analysiert. Zu Beginn dieser Experimente 
war das 2-DE Proteinmuster in Urinproben aufgrund fehlender angemessener 
Vorbehandlung der Urinproben für die 2D-Elektrophorese kaum bekannt. Daher 
waren die Untersuchungen zunächst auf Methoden zur Aufbereitung der Urinproben, 
die die bestmögliche Proteinerhaltung gewährleisten, fokussiert. Nach 
experimenteller Optimierung der 2D-Elektrophorese wurden 2D-Proteinmuster der 
Urinproben analysiert, um mittels massensprektrometrischer Analysen, Western Blot-
Analysen und Immunhistochemie Proteine zu identifizieren, die mit 
Harnblasenkarzinomen assoziiert sind. Beim Harnblasenkarzinom handelt es sich 
um die siebthäufigste Krebstodesursache beim Mann und die neunthäufigste 
Krebstodesursache bei der Frau. Harnblasentumorwachstum- und metastasierung 
sowie der Übergang von einem oberflächlichen, nicht-invasiven in einen invasiven 
Tumorphänotyp sind stark verknüpft mit der Aktivierung der Angiogenese und somit 
der Tumorvaskularisierung. Dieser Prozess wird geregelt durch ein Gleichgewicht 
zwischen angiogenetischen Aktivatoren und Inhibitoren. 
In der vorliegenden Arbeit wurden Orosomucoid (ORM) und humanes Zink-alpha-2-
Glykoprotein (ZAG) anhand der 2D-Elektrophorese als im Urin von 
Harnblasenkarzinompatienten im Vergleich zu normalen Urinproben erhöhte 
Markerproteine identifiziert. Immunhistochemische Untersuchungen lassen 
vermuten, dass zusätzlich zu Tumorzellen auch ein Teil der gewebaansässigen 
inflammatorischen Zellen und Endothelzellen tumorassoziierter Blutgefäße die Quelle 
für den ORM-Anstieg in Urinproben von Harnblasenkarzinompatienten darstellen 
könnten. Bei ORM handelt es sich um ein Akute-Phase-Protein, welches bei akuten 
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Infektionen, Entzündungen und Tumorerkrankungen erhöht ist. In neueren 
Publikationen konnte gezeigt werden, dass ORM einen Komplex mit der aktiven 
Form von Plasminogen-Aktivator-Inhibitor-1 (PAI-1) in Thymosin- β4 (T β4)-
aktivierten, aber nicht in ruhenden Endothelzellen eingeht. Unsere weitergehenden 
Untersuchungen zielten auf die Ermittlung einer möglichen Rolle von ORM in der 
Angiogenese. Sowohl die hier präsentierten Ergebnisse als auch Daten der 
Arbeitsgruppe Sorensson zeigen, dass neben Tumorzellen auch humane vaskuläre 
Endothelzellen (HDMECs) ORM endogen exprimieren. Zur funktionellen 
Charakterisierung von ORM in Endothelzellen wurde ORM überexprimiert und 
gesilenct. Anhand von in-vitro-Angiogeneseassays mit Überständen ORM-
überexprimierender und –gesilencter HDMECs konnte gezeigt werden, dass ORM 
die VEGF-induzierte endotheliale Tubeformierung steigert. Diese unterstützende 
Wirkung von ORM konnte potentziert werden durch simultane Behandlung der 
HDMECS mit VEGF, ORM und PAI-1-Antikörper. 
Die Daten zeigen erstmalig, dass ORM erhöht ist in Urinproben von 
Harnblasenkarzinompatienten und proangiogenetisch wirkt durch die Verstärkung 
des tubeformierenden Effektes von VEGF. Dieser unterstützende Effekt konnte 
signifikant gesteigert werden durch zusätzliche Blockade von PAI-1. 
Zusammenfassend scheint die Interaktion zwischen ORM und PAI-1 und dem Anti-
PAI-1-System entscheidend involviert zu sein in die VEGF-vermittelte Angiogenese 
und möglicherweise in die Vaskularisierung des Harnblasenkarzinoms. 
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siRNA  Small interfering RNA 
TAE   Tris-acetate-EDTA 
TBP   Tributyle phosphin 
Abbreviations XIV
TBS-T  Tris buffered saline with tween 
TE   Tris-EDTA 
TEMED  Tetramethylethylendiamin 
TFA    Trifluoroacetic acid buffer 
TFB   Transformation Buffer 
TRIS  Tris(hydroxymethyl)aminomethane 
U   Units 
UV   Ultra violate 
V   Volt 
VEGF  Vascular endothelial growth factor  
VEGFR  Vascular endothelial growth factor receptor 
Vh   Volt-hour 
WHO  World Health Organization 
Wt   Wild-type 
ZAG   Human zinc-alpha-2-gylcoprotein 
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1 Introduction 
 
The field of proteomics has become an increasingly important part of life sciences, 
especially after completion of the human genome sequence. Proteome analysis 
includes separation, identification, and quantitation of proteins from biological 
samples with the purpose of revealing the function of living cells. Applications range 
from prognosis of many types of cancer over drug development to monitoring of 
environmental pollution. 
The study of genes cannot provide much information on the properties of proteins, 
because the molecules responsible for cellular functions (e.g. signal transduction) are 
proteins. Proteins may impose more than 200 different types of post-translational 
modification, including phosphorylation, glycosylation, acetylation, deamination, 
farnesylation, myristolation, palmitoylation, and proteolysis (Krishna and Wold, 1993). 
Such a wide range of modifications cannot be predicted purely from DNA sequences. 
Only through the study of proteins themselves their characteristics and functions can 
be expounded. From the data obtained from studies of the genome project, an 
estimated number of proteins encoded by the genome are known. However, it is 
difficult to predict the actual numbers of proteins encoded based on genomic data, for 
a number of reason (Eisenberg et al., 2000). Firstly, the exon-intron cannot be 
accurately predicted from genomic DNA (Dunham et al., 1999) i.e. genomic 
information needs to be integrated with data obtained from protein studies to confirm 
the presence of a specific gene. Secondly, alternative splicing of a transcript can 
yield more than one protein product (Newman, 1998). Therefore, the direct analysis 
of mRNA or genome does not reflect the exact number of protein products in a cell. 
Thirdly, as a result of compartmentalization and translocation, the same protein can 
be found with different properties and functions in different locations (Fig. 1) 
(Colledge and Scott, 1999). 
These problems can only be solved by proteomics, which can directly identify the 
proteins and provide the genomic information by the appropriate integration of 
genomic and proteomic data (Fig. 2). Scientists worldwide are applying proteomic 
technology to solve problems which cannot be resolved by traditional methods. 
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Figure 1: The flow of genomic information to protein products.  Different epigenetic processes 
leading to physically and/or functionally variable forms of protein isoforms from a single gene 
sequence. The concept of one-gene to one-protein is over-simplified since an RNA can be 
differentially spliced and can produce various protein products.The protein can be exposed to more 
than 200 different types of post-translational modifications. Compartmentalization and translocation 
result in the same protein can be found with different properties and functions in different locations 
(Lau et al., 2003). 
 
1.1 Proteomics 
 
The term proteome refers to all the proteins expressed by a genome, and thus 
proteomics involves the identification of proteins in the body and the determination of 
their role in physiological and pathological processes. 
 
 
 
 
Figure 2: Proteomics and genomics integration. Representation of categories, potential 
applications of proteomics, and the benefits of integrating proteomic and genomic data (Lau et al., 
2003). 
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The studies of proteomics give a chance for the characterization of all or selected 
proteins expressed within a given cell and can outline the flow of information within 
that protein network (Petricoin et al., 2004). It is estimated that more than 500,000 
proteins comprise the human proteome, derived from ~35,000 genes in the human 
genome (Banks et al., 2000; Stein, 2004). Proteomics offer more complexity but 
potentially more specificity than examining genes alone. The study of proteomics can 
generally be divided into two categories: (i) the characterization of protein expression 
and (ii) the characterization of protein function. 
Expression proteomics evaluate cellular protein production encoded by those genes 
active in a cell and present in the target organ. It exposes the differential expression 
of proteins between healthy and diseased states. The technologies applied to 
expression proteomics allow investigation of protein expression in multiple sources 
including tissue as well as serum and urine. 
Functional proteomics evaluate the activation state of and/or interactions between 
proteins and can be used to map the extensive network of signaling pathways in a 
cell. Mapping protein-protein interactions can be useful due to discovery of new 
binding interactions which may give insight into new proteins that are involved in 
cancer as well as novel oncogenes or provide evidence of common downstream 
events shared by two distinct signaling networks. Further information of how various 
pathways intersect can help in developing therapeutic interventions directed against 
these pathway targets (Cai et al., 2004). 
There are several major technologies used in proteomics. The first technology is 
necessary to separate proteins from each other. Two-dimensional polyacrylamide gel 
electrophoresis (2-DE) is currently the method of choice for separation of complex 
protein mixtures such as in cell and tissue extracts or body fluids. 
 
1.2  Technology of proteomics: 2-Dimensional Gelelectrophoresis (2-DE) 
 
2-DE can provide protein databases for qualitative and quantitative analyses of 
protein expression in a wide range of biochemical, biological and biomedical 
investigations (Celis et al., 1989). This technique separates proteins in two steps, 
according to two independent properties: the first-dimension is isoelectric focusing 
(IEF), which separates proteins according to their isoelectric points (pI); the second-
dimension is SDS-polyacrylamide gel electrophoresis (SDS-PAGE), which separates 
proteins according to their molecular weights (MW). In this way, complex mixtures 
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consisted of thousands of different proteins can be resolved and the relative amount 
of each protein can be determined. 
1.2.1 Sample preparation 
Appropriate sample preparation is essential for good 2–DE results. The optimal 
procedure must be determined empirically for each sample type. An ideal process 
should result in complete solubilisation, disaggregation, denaturation, and reduction 
of the proteins in the sample. It is important to have a clear idea of what is desired in 
the final 2-DE result when developing a sample preparation strategy. Different 
treatments and conditions are required to solubilise different types of protein 
samples; some proteins are naturally found in complexes with membranes, nucleic 
acids, or other proteins; some proteins form various non-specific aggregates; and 
some proteins precipitate when removed from their natural environment. The 
effectiveness of solubilisation depends on the choice of cell disruption method, 
protein concentration and dissolution methods, choice of detergents, and 
composition of the sample solution. The composition of the sample solution is 
particularly critical for 2-DE, because solubilisation treatments for the first-dimension 
separation must not effect isoelectric point (pI), nor leave the sample in a highly 
conductive solution. In general, concentrated urea as well as one or more detergents 
is used. 
1.2.2 Protein extraction 
The extraction of proteins from a cell requires the disruption of the cell membrane 
and the solubilization of the proteins contained in the cell and the cell membrane. An 
extraction buffer should extract all proteins, denature them, and exclude nucleic acids 
and cell debris. The most successful and widely used solubilising buffers contain 
chaotropic agents that will disrupt the hydrogen bonding, a combination of several 
detergents that prevents hydrophobic interactions between hydrophobic side chains 
and helps solubilize the proteins, and a reducing agent that breaks the disulfide 
bridges initially formed between two cysteine residues (Chevallet et al., 1998; Tastet 
et al., 2003). Such detergents will achieve cell disruption, removal of interfering 
agents, and solubilization and denaturing of proteins (Gorg et al., 2004; Herbert, 
1999). 
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1.2.2.1 Chaotropic agent 
 
The use of urea and thiourea (Fig. 3A,B) increase the solubility of proteins by 
disrupting the hydrogen bonding (Rabilloud et al., 1997). Urea solubilises and 
denaturates proteins, unfolding them to expose internal ionisable amino acids. 
Commonly 8 M urea is used, but the concentration can be increased to 9 or 9.8 M. 
Using thiourea in addition to urea improves solubilisation, particularly of hydrophobic 
membrane proteins (Molloy, 2000; Rabilloud, 1998). 
Figure 3: Structure of Urea and Thiourea. Two chaotropic reagents, urea (A) and thiourea (B) used 
for the protein extraction. The presence of these two reagents in the lysis buffer allows for the 
solubilization of non-soluble proteins by disrupting the hydrogen bonding that are formed between the 
oxygen of the carbonyl group of an amino acid with the hydrogen of an amino group of another amino 
acid. 
 
1.2.2.2 Detergents 
 
Detergents prevent hydrophobic interactions between hydrophobic side chains from 
occurring and allow for better solubility of proteins. SDS is considered the most 
efficient detergent for the solubilisation of proteins (Boucherie et al., 1995; Harder et 
al., 1999), but because of its ionic nature, it may interfere with the first dimension of 
2-DE and it has been reported to cause horizontal streaks on the gel (Gorg et al., 
2004). Non-ionic detergents like OG (Octylglucopyranoside) and zwitterionic 
reagents like CHAPS (3-[(3-cholamidopropyl)dimethylamino]-1-propanesulfonate) are 
being favoured over SDS use (Kersten et al., 2002; Rabilloud et al., 1997; Rabilloud 
et al., 1999) (Fig. 4A-C). A combination of several non-ionic and zwitterionic 
detergents should be used because no one detergent is perfect for the solubilization 
of most of the hydrophobic proteins (Schuck et al., 2003). 
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Figure 4: Structure of detergents used in solubilisation of proteins. (A) Sodium Dodecyl Sulfate 
(SDS), an anion detergent; (B) Octyl glucopyranoside (OG) a non-ionic detergent; and (C) 3-[(3-
cholamidopropyl)dimethylamino]–1– propanesulfonate (CHAPS) a zwitterionic detergent. 
 
1.2.2.3 Reducing agents 
 
To obtain well resolved spots, disulfide bridges should be cleaved to achieve total 
denaturation of the protein. This can be done using a reducing agent like 
Dithiothreitol (DTT) (Fig. 5). 
 
Figure 5: Structure of dithiothreitol (DTT). A reducing agent used to cleave the disulfide bridges 
that can form between two cysteine residues to achieve complete denaturation of proteins and 
increase their solubility. 
 
However, DTT is a weak acid which will migrate to the basic region of the IPG strip 
when the sample is loaded for isoelectric focusing (IEF) and will only reduce proteins 
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in that region, necessitating the introduction of excess DTT at the cathode (Hoving et 
al., 2002). Tributyl phosphine (TBP) (Fig. 6) was reported as an alternative reducing 
agent (Herbert et al., 1998). 
 
 
 
Figure 6: Structure of tributylphosphine (TBP). A reducing agent used in 2-DE process. 
1.2.3 First dimension: Isoelectric focusing (IEF) 
IEF is an electrophoretic method that separates proteins according to their isoelectric 
points (pI). Proteins are amphoteric molecules; they carry either positive, negative, or 
zero net charge, depending on the pH of their surroundings (Fig. 7). The net charge 
of a protein is the sum of all the negative and positive charges of its amino acid side 
chains and aminoand carboxyl-termini. The isoelectric point (pI) is the specific pH at 
which the net charge of the protein is zero. Proteins are positively charged at pH 
values below their pI and negatively charged at pH values above their pI. If the net 
charge of a protein is plotted versus the pH of its environment, the resulting curve 
intersects the x-axis at the isoelectric point (Fig. 7). The presence of a pH gradient is 
critical to the IEF technique. In a pH gradient, under the influence of an electric field, 
a protein moves to the position in the gradient where its net charge is zero. A protein 
with a positive net charge migrates toward the cathode, becoming progressively less 
positively charged as it moves through the pH gradient until it reaches its pI. A 
protein with a negative net charge migrates toward the anode, becoming less 
negatively charged until it also reaches zero net charge. If a protein should diffuse 
away from its pI, it immediately gains charge and migrates back. 
This is the focusing effect of IEF, which concentrates proteins at their isoelectric 
points and allows proteins to be separated on the basis of very small charge 
differences. 
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Figure 7: Structures of protein as amphoteric molecules, isoelectric point of proteins. 
 
The resolution is determined by the slope of the pH gradient and the electric field 
strength. IEF is therefore performed at high voltages (typically in excess of 1000 V). 
When the proteins have reached their final positions in the pH gradient, there is very 
little ionic movement in the system, resulting in a very low final current (typically 
below 1 mA). IEF of a given sample in a given electrophoresis system is generally 
performed for a constant number of Volt-hours (Volt-hour (Vh) being the integral of 
the volts applied over the time). 
IEF performed under denaturing conditions gives the highest resolution and the 
cleanest results. Complete denaturation and solubilization is achieved with a mixture 
of urea and detergent, ensuring that each protein is present in only one configuration 
and aggregation and intermolecular interaction is minimized. 
An immobilized pH gradient (IPG) is created by covalently incorporating a gradient of 
acidic and basic buffering groups into a polyacrylamide gel at the time it is cast. The 
general structure of Immobiline reagents is: 
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CH2 = CH–C–NH–RO 
R = weakly acidic or basic buffering group. 
 
Figure 8: Structure of polyacrylamide gel matrix. Graphical representation of the polyacrylamide 
matrix with attached buffering groups. 
Immobilized pH gradients are formed using two solutions, one containing a relatively 
acidic mixture of acrylamido buffers and the other containing a relatively basic 
mixture. The concentrations of the various buffers in the two solutions define the 
range and shape of the pH gradient produced. Both solutions contain acrylamide 
monomers and catalysts. During polymerization, the acrylamide portion of the buffers 
copolymerizes with the acrylamide and bisacrylamide monomers to form a 
polyacrylamide gel. The graphical representation of polyacrylamide matrix with 
attached buffering groups is shown in figure 8. 
The IEF is the most critical step of the 2-DE process. The proteins should be 
solubilised without charged detergents, usually in high concentrated urea solution, 
reducing agents and chaotrophs. To obtain high quality data it is essential to achieve 
low ionic strength conditions before the IEF it self. Since different types of samples 
differ in their ion content, it is necessary to adjust the IEF buffer and the electrical 
profile to each type of sample. 
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1.2.4 Second dimension: SDS-PAGE 
In the second dimension, the protein molecules are separated vertically according to 
their molecular weight. Sodium dodecyl sulfate treatment denatures proteins (that is, 
it unfolds them into long, straight molecules) and coats all proteins essentially in 
proportion to their mass. 
The pores of the second dimension gel sift proteins according to size because 
dodecyl sulphate coats all proteins essentially in proportion to their mass. The 
coating of the protein in negatively-charged SDS allows the proteins to migrate as 
ellipsoids with a uniform negative charge-to-mass ratio, with mobility related 
logarithmically to mass. Proteins are therefore separated horizontally based on their 
isoelectric point and vertically based on their molecular mass. 
SDS is an anionic detergent, that, when in solution in water, forms globular micelles 
composed of 70–80 molecules with the dodecyl hydrocarbon moiety in the core and 
the sulfate head groups in the hydrophilic shell. SDS and proteins form complexes 
with a necklace-like structure composed of protein-decorated micelles connected by 
short flexible polypeptide segments (Ibel et al., 1990). The result of the necklace 
structure is that large amounts of SDS are incorporated in the SDS-protein complex 
in a ratio of approximately 1.4 g SDS/g protein. SDS masks the charge of the 
proteins themselves and the formed anionic complexes have a roughly constant net 
negative charge per unit mass. Besides SDS a reducing agent such as dithiothreitol 
(DTT) is also added to break any -S-S-linkages present in the proteins. When 
proteins are treated with both SDS and a reducing agent, the degree of 
electrophoretic separation within a polyacrylamide gel depends largely on the 
molecular weight of the protein. In fact, there is an approximately linear relationship 
between the logarithm of the molecular weight and the relative distance of migration 
of the SDS-polypeptide complex. 
The most commonly used buffer system for second-dimension SDS-PAGE is the tris-
glycine system described by Laemmli (Laemmli, 1970). This buffer system separates 
proteins at high pH, which confers the advantage of minimal protein aggregation and 
clean separation even at relatively heavy protein loads. The Laemmli buffer system 
has the disadvantage of a limited gel shelflife. 
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1.2.5 Equilibration 
The equilibration step saturates the IPG strip with the SDS buffer system required for 
the second-dimension separation. The equilibration solution contains buffer, urea, 
glycerol, reductant, SDS, and dye. An additional equilibration step replaces the 
reductant with iodoacetamide. Equilibration introduces reagents essential for the 
second-dimension separation. 
Urea (6 M) together with glycerol reduces the effects of electroendosmosis by 
increasing the viscosity of the buffer (Gorg et al., 1985). Electroendosmosis is due to 
the presence of fixed charges on the IPG strip in the electric field and can interfere 
with protein transfer from the IPG strip to the second-dimension gel. 
Glycerol (30%) together with urea reduces electroendosmosis and improves transfer 
of protein from the first to the second-dimension (Gorg et al., 1985). 
DTT preserves the fully reduced state of denatured, unalkylated proteins. 
Sodium dodecyl sulfate (SDS) denatures proteins and forms negatively charged 
protein-SDS complexes. The amount of SDS bound to a protein, and therefore the 
additional negative charge, is directly proportional to the mass of the protein. Thus, 
electrophoresis of proteins through a sifting gel in the presence of SDS separates 
proteins on the basis of molecular mass. 
Iodoacetamide alkylates thiol groups on proteins, preventing their reoxidation during 
electrophoresis. Protein reoxidation during electrophoresis can result in streaking and 
other artifacts. Iodoacetamide also alkylates residual DTT to prevent point streaking 
and other silver-staining artifacts. Iodoacetamide is introduced in a second 
equilibration step. The second equilibration with iodoacetamide is also used to 
minimize unwanted reactions of cysteine residues (i.e. when mass spectrometry is to 
be performed on the separated proteins). 
Tracking dye (bromophenol blue) allows monitoring of electrophoresis. 
1.2.6 Identification of proteins 
After first and second dimension the proteins are detected by color, immunoanalysis, 
or prebound fluorescent dyes, unique spots are quantified by their staining intensity. 
Spots of interest are excised from gel and subjected to protease digestion, and 
peptide fragments can be examined using Mass Spectrometry. Mass spectrometry 
measures the mass-to-charge ratio (m/z) of ionized proteins as they migrate through 
an electric or a magnetic field. Proteins are analyzed and identified based on unique 
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spectrometric signatures. These features allow identification of structural features 
such as phosphorylation or methylation. Trypsin digestion of proteins yields peptides 
that are amenable to MS sequencing. Coupling MS with MALDI is another method by 
which proteins can be identified. 
 
1.3 Urinary proteomics 
 
1.3.1 Formation of urine 
Urine is formed in the kidney by ultrafiltration from the plasma to eliminate waste 
products, for instance urea and metabolites. Although the kidney accounts for only 
0.5% of total body mass, a large volume of plasma (350-400 ml/100 g tissue/min) 
flows into the kidney, generating a large amount of ultrafiltrate (150-180 l/day) under 
normal physiologic conditions. Components in the ultrafiltrate such as water, glucose, 
amino acids, and inorganic salts are selectively reabsorbed, and less than 1% of 
ultrafiltrate is excreted as urine. Serum proteins are filtered based on their sizes and 
charges at the glomeruli (Haraldsson and Sorensson, 2004). 
After passing through glomeruli, abundant serum proteins such as albumin, 
immunoglobulin light chain, transferrin, vitamin D binding protein, myoglobin, and 
receptor-associated protein are reabsorbed, mainly by endocytic receptors, megalin, 
and cubilin in proximal renal tubules (Christensen and Gburek, 2004; Maunsbach, 
1997). Thus, protein concentration in normal urine is very low (less than 100 mg/l 
when urine output is 1.5 l/day), and normal protein excretion is less than 150 mg/day. 
This is about a factor 1000 less compared with other body fluids such as plasma. 
Excretion of more than 150 mg/day protein is defined as proteinuria and is indicative 
of glomerular or reabsorption dysfunction. 
1.3.2 Sources of urinary proteins 
Urinary proteins include soluble proteins and protein components of solid phase 
elements of urine (Tab. 1). Solid phase elements consist of “sediments” that can be 
precipitated at low centrifugation speeds and “exosomes” that are of very low density 
and sediment only with ultracentrifugation. Prefractionation of these components can 
be useful as a means of enriching for markers of particular types of disease. A study 
of urine collected from normal human adult subjects indicated that, of the total urinary  
protein excreted, 48% was contained in sediments, 49% was soluble, and the 
remaining 3% was in exosomes (Zhou et al., 2006). 
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   Sources of urinary proteins               Comments 
  
 
• Glomerular filtration of plasma proteins 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
• Epithelial cell secretion of soluble proteins. 
 
 
 
 
• Epithelial cells 
 
a. Whole cell sheding  
 
 
 
b. Plasma membrane and intracellular 
 component shedding 
 
 
 
 
c. Exosome secretion 
 
 
 
• Other cells 
 
 
 
Table 1: Sources of urinary proteins. (Pisitkun et al., 2004). 
 
The soluble proteins in urine are derived largely from glomerular filtration. The 
glomerular filter effectively retards passage of high molecular weight proteins. 
However, even with very low sieving coefficients, proteins that are abundant in the 
blood plasma such as albumin and various globulins can pass the glomerular filter in 
substantial amounts to enter the lumen of the nephron. Beyond this, peptides and 
small proteins (10 kDa) are freely filtered by the glomerulus. Most of the proteins and 
peptides that pass the glomerular filter are scavenged and proteolyzed in the 
proximal tubule by highly specialized apical uptake processes that involves receptor-
Soluble Proteins 
Normally present (<150 mg/day) 
 
Defects in glomerular filter increase high   
molecular weight protein (e.g. albumin) 
excretion 
 
Defects in proximal tubule reabsorption or   
abnormal production of low molecular weight 
plasma proteins increase low molecular weight 
protein (e.g. β2-microglobulin, immunoglobulin 
light chains, retinol-binding protein, and 
aminoacids) excretion 
Solid phase components 
Via exocytosis (e.g. epidermal growth factor) or 
glycosylphosphatidylinositol-anchored protein 
detachment (e.g. Tamm-Horsfall protein)  
Increased cell number compatable with several 
diseases including acute tubular necrosis (e.g. 
renal tubule cell sheding) and glomerular 
diseases (e.g. podocyte shedding). 
Could be due to nonspecific, nephrotoxic, or 
apoptotic processes. 
Normal process
In certain diseases, red blood cells, white blood 
cells, or tumor cells (e.g. bladder cancer and 
lymhome) can be present in urine.  
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like recognition of the polypeptide molecules (Christensen and Birn, 2001; 
Christensen, 2002). Thus, a change in the amount of a given soluble protein that 
reaches the final urine can result from a change in its concentration in the blood 
plasma, a change in the function of the glomerular filter, or an alteration in the 
proximal tubule scavenging system (Fig. 9). 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Mechanism of urinary exosome formation and excretion. Apical membrane proteins 
undergo endocytosis followed by targeting to the.multivesicular body (MVB). The membrane proteins 
are segregated initially in the MVB outer membrane and then are internalized by membrane 
invagination, encapsulating cytosolic proteins in the process. After accumulation of numerous internal 
vesicles, the outer membrane of the MVB fuses with the apical plasma membrane releasing its 
internal vesicles, called exosomes, into the urinary space. Exosomes contain both membrane and 
cytosolic proteins (Hoorn et al., 2005). 
Based on these mechanisms, changes in excretion rate of specific urinary proteins 
can be indicative of systemic disease, glomerular disease, or diseases affecting the 
proximal tubule, respectively. Some of the soluble proteins in urine originate as 
membrane-bound proteins that are proteolytically cleaved from their membrane 
attachments. 
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1.4  Bladder cancer 
 
Bladder cancer is one of the most common cancer type occuring worldwide. The rate 
for these tumors is highest in developed countries, where they rank as the sixth most 
frequent neoplasm. The disease currently ranks as the fourth most common cause of 
cancer death in men and the eighth in women. Estimated new cases are 63,210 and 
deaths from bladder cancer are 13,180 in the United States in 2005 (American 
Cancer Society, Atlanta, 2005). The incidence of bladder cancer increases with age 
and is particularly high after age of sixty and is uncommon before age fourty. The 
urinary bladder has a flat, smooth, shiny, watertight lining consisting of layers of cells 
tightly connected with each other. The lining of the bladder can be imagined to be 
similar to the lining in the oral cavity (mouth). Underneath this lining is the muscle 
tissue of the bladder. The muscle is responsible for pushing out the urine at the time 
of voiding. The capacity of bladder is around 350-400 cc in adults. The bladder lies in 
the pelvis anterior and inferior to the peritoneal cavity, and posterior to the pubic 
bones. In the female, it rests directly on the muscular pelvic floor, while in the male 
the prostate gland is attached directly to the base of the bladder and separates it 
from its muscular support. 
Bladder cancer is an abnormal growth or tumor arising from the lining of the bladder. 
The cells grow abnormally fast causing a tumor to sprout up from the flat lining into a 
growth projecting into the interior of the bladder cavity. Bladder cancer occurs within 
the domain of human neoplasms by many different types of etiological factors such 
as some aromatics (i.e. xylamine, β-naphtylamine, benzydine, 4-nitro diphenyl), 
coffee, artificial sweeteners and smoking (Cohen et al., 1979; Morrison et al., 1982; 
Wynder and Stellman, 1977). Most of bladder cancers present as superficial disease 
and are amenable to local excision by endoscopic resection. The rate of recurrence 
ranges from 50% to 75% and the rate of progression in stage is from 15% to 25%. 
Cystoscopy is the gold standard for routine surveillance for bladder tumor recurrence, 
with biopsy of suspicious lesions and histopathologic evaluation required to confirm 
the diagnosis (Tsihlias and Grossman, 2000). 
1.4.1 Staging of bladder cancer 
The clinical staging of carcinoma of the bladder is determined by the depth of 
invasion of the bladder wall by the tumor (Fig. 10). Based on morphologic evaluation 
and natural history, urothelial neoplasms have been classified into two groups having 
Introduction 16 
distinct behavior and prognosis; (i) low-grade tumors (always papillary and usually 
superficial) and (ii) high-grade tumors (either papillary or non-papillary and often 
invasive). Clinically, superficial bladder tumors (stages Ta, Tis, and T1) account for 
75% to 85% of neoplasms, whereas the remaining 15% to 25% are invasive (T2, T3, 
T4) or metastatic (N+, M+) lesions at the time of initial presentation (Rabbani and 
Cordon-Cardo, 2000). The American Joint Committee on Cancer (AJCC) has 
designated staging by TNM classification to define bladder cancer (American Joint 
Committee on Cancer, 2002) (Tab. 2). AJCC stage grouping is shown in table 3. 
 
  
 
 
 
 
 
 
 
Figure 10: Representation of bladder cancer stages. Scheme for bladder tumor classification 
based-on the depth of tumor invasion into the bladder wall (From Hautmann and Huland, Urology, 
Springer-Publisher). 
1.4.2 Cellular classification 
More than 90% of bladder carcinomas are transitional cell carcinomas derived from 
the uroepithelium. About 6% to 8% are squamous cell carcinomas and 2% are 
adenocarcinomas (Mostofi et al., 1988). Adenocarcinomas may be either of urachal 
origin or of nonurachal origin; the latter type is generally thought to arise from 
metaplasia of chronically irritated transitional epithelium (Wilson et al., 1991). 
Pathologic grade, which is based on cellular atypia, nuclear abnormalities, and the 
number of mitotic figures, is of great prognostic importance. Resection of the tumor in 
his entirety, with inclusion of the lamina propria and muscularis propria, and biopsy of 
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all endoscopically suspicious areas (i.e., nontraumatized erytematous areas) are 
generally performed to ensure proper staging. 
 
TNM Definitions 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Ta Noninvasive papillary carcinoma 
Tis Carcinoma in situ (i.e., flat tumor) 
T1 Tumor invades subepithelial connective tissue 
T2    
                    pT2a 
                    pT2b 
Tumor invades muscle 
Tumor invades superficial muscle (inner half) 
Tumor invades deep muscle (outer half) 
T3    
                    PT3a 
                    PT3b 
Tumor invades perivesical tissue 
Microscopically 
Macroscopically (extravesical mass) 
T4    
                    PT4a    
                    PT4b 
Tumor invades any of the following ; prostate, uterus, vagina, pelvic wall, or 
abdominal wall 
Tumor invades the prostate, uterus, vagina 
Tumor invades the pelvic wall, abdominal wall 
Regional lymph nodes (N) 
NX Regional lymph nodes cannot be assessed 
NO No regional lymph node metastasis 
N1 Metastasis in a single lymph node, =2 cm in greatest dimension 
N2 Metastasis in a single lymph node, >2 cm but =5 cm in greatest dimension; or multiple lymph nodes, =5 cm in greatest dimension   
N3 Metastasis in a lymph node, >5 cm in greatest dimension 
Distant Metastasis (M) 
MX Distant metastasis cannot be assessed 
MO No distant metastasis 
M1 Distant metastasis 
 
Table 2: Staging of bladder cancer. Definition of bladder cancer which was designed by American 
Joint Committee on Cancer (AJCC) using TNM classification. (Lamm, 1994). 
 
Directed biopsies may be performed to evaluate adjacent or distant mucosa if urine 
cytology is positive. Biopsy of the prostatic urethra to evaluate its involvement in the 
overall tumor diathesis (especially in the setting of CIS) is also important (Lee and 
Droller, 2000). 
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AJCC stage groupings 
Stage 0a Ta, N0, M0 
Stage 0is Tis, N0, M0 
Stage I T1, N0, M0 
Stage II T2a, N0, M0; T2b,N0, M0 
Stage III T3a, N0, M0; T3b, N0, M0; T4a, N0, M0  
Stage IV T4b, N0, M0; Any T, N1,M0; Any T, N2,M0; Any T, N3,M0; Any T, any N,M1  
 
Table 3: AJCC stage groupings. Classification of bladder cancer by American Joint Committee on 
Cancer (AJCC) (Lamm, 1994). 
 
1.5 Clinical proteomics and biomarkers 
 
Many diseases manifest themselves through severe changes in human physiology, 
which forms the basis for clinical chemistry and confers its value in diagnoses and 
subsequent therapeutic interventions (Bischoff and Luider, 2004). Clinical proteomics 
include the analysis of proteins expressed by the genome of an organism, with the 
typical aim being the evaluation of quantitative changes that occur as a function of 
disease, treatment, or environment (Somiari et al., 2003). Proteomics strategies are 
being used to identify disease-specific protein markers called biomarkers that could 
provide the basis for the development of new diagnosis methodologies, treatments, 
and early detection of diseases particularly of cancer (Hanash, 2000; Somiari et al., 
2003). Already for a number of years, 2-DE followed by protein identification using 
mass spectrometry has been the primary technique for biomarker discovery in 
conventional proteomic analyses (Gorg et al., 2000; Hanash, 2000). 
 
1.6 Urinary biomarkers 
 
Because urine can be collected noninvasively in large amounts, it provides an 
attractive alternative to blood plasma as a potential source of disease biomarkers 
(Thongboonkerd et al., 2004). The use of urinary biomarkers to diagnose disease is a 
long-standing practice. Studies to identify biomarkers of disease in urine have been 
an underlying component of investigative medicine throughout the 20th century and 
early 21st century. These studies have been based on knowledge of the 
pathophysiology of disease to identify biomarkers that could be tested in clinical 
trials. Large scale proteomics profiling of normal human urine samples has revealed 
the presence of at least 1000 different protein gene products and many more peptide 
fragments of larger proteins (Castagna et al., 2005; Jurgens et al., 2005; Oh et al., 
2004; Pisitkun et al., 2004; Smith et al., 2007; Sun et al., 2005). There is hope, 
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therefore, for discovery of urinary protein excretion profiles that can be used clinically 
for tasks such as early detection and classification of diseases particularly of cancer, 
choice of therapeutic agents, assessment of prognosis, and monitoring of a particular 
therapeutic regimen. Several potential diagnostic markers for bladder cancer have 
been identified, including nuclear matrix protein 22, bladder tumor antigen, and 
telomerase. 
 
1.7 Tumor angiogenesis 
 
One of the critical events required for cancer growth is the development of a new 
network of blood vessels. This is provided by angiogenesis as well as postnatal 
vasculogenesis (Folkman and D'Amore, 1996). Angiogenesis is defined as the 
sprouting of new vessels from pre-existing blood vessels (Folkman, 2003; Luttun and 
Carmeliet, 2004), while postnatal vasculogenesis describes the formation of new 
vessels by endothelial precursor cells circulating in peripheral blood or derived from 
the bone marrow (Asahara and Kawamoto, 2004; Gehling et al., 2000; Rafii et al., 
2002) from the vessels wall as recently demonstrated (Zengin et al., 2006). 
Angiogenesis as well as postnatal vasculogenesis are regulated by angiogenic 
activators and inhibitors (Hanahan and Folkman, 1996). The structural formation and 
maturation of blood vessels during vasculogenesis and angiogenesis is a very 
complex process that runs in successive steps including proliferation and tube 
formation of endothelial cells, construction of the basement membrane, integration of 
peri-endothelial cells into the vascular wall, and embedding of blood vessels into the 
peri-vascular tissue (Ergun et al., 2006; Folkman et al., 1989; Folkman and D'Amore, 
1996). Numerous angiogenic factors including vascular endothelial growth factor 
(VEGF), fibroblast growth factor-2 (FGF-2), angiopoietins (Ang1, Ang2), and their 
receptors, which belong to the receptor tyrosine kinase family, are involved in several 
steps of this process (Maisonpierre et al., 1997). 
VEGF is the key regulator of physiological and pathological angiogenesis and acts as 
a survival factor for endothelial cells (EC), both in vitro and in vivo (Ferrara, 2005). 
The biological effects of VEGF are mediated by two receptor tyrosine kinases 
(RTKs), vascular endothelial growth factor receptor-1 (VEGFR-1) and VEGFR-2 
(Ferrara et al., 2003).  Particularly, the interaction of VEGF with its receptor VEGFR-2  
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Figure 11: Vascular destabilization and initiation of angiogenesis. A normal stabilized capillary 
with a dense BM (gray) enclosing both endothelial cells (green) and pericyte (red) (A) will be 
destabilized by action of pro-angiogenic factors as exemplarily shown by VEGF and Ang2 leading to 
endothelial fenestration (fn), opening of inter-endothelial contacts (iec), development of 
transendothelial gaps (gap), degradation of BM and finally detachment of pericytes from the 
endothelial layer (B). These morphogenetic events are accompanied by an abnormal vascular 
leakiness. The further duration of pro-angiogenic action would finally lead to sprouting of new nascent 
and instable blood vessels (C), a process defined as angiogenesis (Adopted from Ergün et al., Cancer 
Encyclopedia, 2007, in press). 
 
(known also as KDR in human or Flk-1 in mouse) intiates the angiogenic activity by 
causing the structural destabilization of the vascular wall with subsequently increased 
vascular leakeness (Ergun et al., 2006; Thurston et al., 2000). Also angiopoietin-2 
(Ang2), a partial antagonist of the angiopoietin-1 (Ang1) and both Ang1 and Ang2 act 
via the same tyrosin kinase receptor Tie-2, is essentially involved in the 
destabiliazion of the vascular wall as shown in figure 11. 
The abnormal vascular leakeness results in the extravasation of enzymes degrading 
the vascular basement membrane. Among these enzymes is the uPA, the urokinase 
type plasminogen activator, a key enzyme involved in the remodelling extracellular 
matrix supporting the migration of endothelial cells and thus the angiogenic activity of 
these cells (Agirbasli, 2005; Rakic et al., 2003). The action of this enzyme is 
modulated by the PAI-1 (plasminogen activator inhibitor-1) which has been shown to 
have a dual role in the interaction with uPA or the receptor of uPA, uPAR (Binder et 
al., 2007). The concerted action of the mentioned factors above howeever results in 
the complete disintegration of endothelial cells of pre-existing blood vessels with 
subsequent migration and proliferation of endothelial cells, and finally in the 
outgrowth of new vessels from pre-existing blood vessels. 
 
1.8 One of urinary proteins: Orosomucoid (ORM) 
 
Orosomucoid (ORM), also known as alpha1-acid glycoprotein (AGP), was firstly 
described in 1950 by Schmid (Schmid, 1950; Schmid, 1953). It belongs to a group of 
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acute phase proteins (APPs) and plays a role in the modulation of the immune 
response to stress, along with many other functions (Schmid K, 1975; Bennet M, 
1980). The relatively high concentration of ORM in the serum of healthy humans is 
known to rise two- to fivefold in response to different conditions such as acute 
infection, inflammatory and lymphoproliferative disorders and cancer (Schmid, 1975). 
The structure of ORM is well characterized and is composed of a polypeptide chain 
containing about 45% carbohydrate including a large amount of fucosylic and sialic 
acid. Thus, its proposed immunomodulatory activities have been attributed to its 
glycosylation pattern, since the strongly fucosylated and sialylated ORM glycoforms 
have the ability to bind E-selectin and to inhibit complement activation (De Graaf et 
al., 1993). 
Type 1 APPs, including  ORM, complement component 3, serum amyloid A, C-
reactive protein, haptoglobin and hemopexin, are regulated by IL-1, IL-6 and 
glucocorticoids and type 2 APP, including the three chains of fibrinogen and several 
proteases inhibitors, are regulated by IL-6- type cytokines and glucocorticoids 
(Baumann et al., 1989). ORM is synthesized in liver and various extrahepatic cell-
types e.g. granulocytes (Fournier T, 2000). IL-1, IL-6 and glucocorticoids are the 
major modulators of ORM gene expression in liver cells (Alam et al., 1993; Baumann 
et al., 1989; Baumann and Gauldie, 1990). In most instances, a strong synergistic 
action is achieved by the combination of the three factors (Alam et al., 1993; 
Baumann et al., 1987). An induced expression of sialyl Lewis X (sLeX) on ORM 
during acute inflammation has been reported, leading to the speculation that it might 
influence the E- or P-selectin-mediated influx of sLeX-expressing leukocytes into 
inflamed areas. It has been suggested that an increased level of sLeX-expressing 
ORM could have a feedback inhibitory effect on the extravasation of leukocytes, by 
competition for the E-selectin adhesion molecules (Lasky, 1992). ORM is thought to 
modify the permeability of the vascular endothelium, possibly by interacting with the 
endothelial glycocalyx (Curry and Michel, 1980). Thus far it has been shown that 
ORM binds to the vascular endothelial cell surface (Fig. 12) and then causes 
transcytosis across the cell without passing the intercellular junction (Predescu et al., 
1998). 
 
Introduction 22 
 
Figure 12: Hypothesis for the inhibition of leukocyte extravasation by ORM. Events leading to 
transmigration of leukocytes to a site of inflammation are summarised. ORM expressing sialyl Lewisx 
interacts with E-selectin expressed at the surface of endothelial cells and compete with leukocytes 
expressing ESL-1, the ligand of E-selectin. Consequently, rolling, adhesion and extravasation of 
leukocytes may then be inhibited. (From E.C. Havenaar, Thesis, Vrije Universiteit, Amsterdam, 
Netherlands.). 
 
1.9 The plasminogen activation system 
 
The plasminogen activation system regulates the formation of the serine protease 
plasmin and subsequent fibrinolysis. The process of fibrinolysis starts with 
conversion of an inactive proenzyme, plasminogen, a 92-kDa single-chain 
glycoprotein consisting of 791 amino acids into the active enzyme, plasmin (Forsgren 
et al., 1987). Plasmin is, in turn, able to degrade fibronectin, laminin, vitronectin, 
proteoglycans, as well as fibrin and activate latent collagenases. Angiogenic growth 
factors induce the expression of tissue-type plasminogen activator (tPA) and 
urokinase-type plasminogen activator (uPA) on the surface of endothelial cells 
(Flaumenhaft et al., 1992; Pepper et al., 1991). Both tPA and uPA are serine-
proteases that can generate plasmin by proteolytic cleavage of its zymogen 
plasminogen. Plasminogen, like fibrinogen and other plasma components of the 
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provisional matrix, is synthesized in the liver and deposited in response to 
hyperpermeability. The formation of plasmin is essential for invasion and migration of 
endothelial cells into the tissue to be vascularized. The plasminogen activation 
system is not limited to endothelial cells. While tPA is almost exclusively expressed 
by endothelial cells (Mandriota and Pepper, 1997), uPA also facilitates migration of 
other cells like epithelial cells, fibroblasts and tumor cells (Del et al., 1990; 
MacDonald et al., 1998). A variety of cell types can bind components of the 
fibrinolytic system, including plasminogen (Miles and Plow, 1985), plasmin (Correc et 
al., 1990), uPA (Vassalli et al., 1985) and tPA (Hajjar et al., 1987). There are two 
main plasminogen activator inhibitors, PAI-1 and PAI-2. Plasminogen activator 
inhibitor type 1 (PAI-1) is the main inhibitor of plasminogen activators (Carmeliet et 
al., 1993; Fay et al., 1992). The PAI in blood represents 60% of plasminogen-
activation inhibitor activity in plasma (Fig. 13). PAI-1 inhibits both tPA and uPA, 
whereas PAI-2 inhibits only uPA. 
 
Figure 13: Plasminogen activation system.  The plasminogen-activator inhibitor 1 (PAI-1) 
molecules is the main plasminogen-activator inhibitor in blood and it is important for fibrin degradation, 
remodelling of ECM and angiogenesis (Agirbasli, 2005). 
 
Unlike the simple digestive proteases, in which only a signaling peptide and a short 
activation domain are attached to the catalytic region, the fibrinolytic proteases bear 
large noncatalytic regions (Patthy, 1985). 
These regions contain functionally autonomous modules, such as "kringle", "growth 
factorlike" or "EGFlike" and "finger" domains, which also occur outside the serine 
protease family. A graphic representation of the domain arrangement in plasminogen, 
uPA and tPA is shown in Fig. 14. 
 
Plasminogen  Plasmin 
PAI-1 
Fibrin 
degradation 
ECM 
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migration 
Angiogenesis 
t-PA /u-PA 
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Figure 14: Graphical representation of the protein domains of plasminogen, tissuetype 
plasminogen activator (tPA) and urokinase (uPA) proenzymes. The kringle (K), Finger (F), 
EGFlike (EGF) and catalytic (CD) domains are marked. The activation sites are indicated by an arrow. 
 
The serine proteinase plasmin consists of two disulfide bond-linked polypeptide 
chains. The N-terminal A chain contains five so called kringle domains. The C-
terminal B chain contains a typical serine proteinase domain, which is responsible for 
catalytic activity (Fig. 15).  Plasmin catalyzes the hydrolysis of peptide bonds on the 
C-terminal side of Lys and Arg residues. Conversion of plasminogen to plasmin can 
be catalyzed by either uPA or tPA. 
The active form of PAI-1 is thought to have an exposed center loop that is available 
for interaction with proteinases (Lawrence et al., 1995; Lawrence, 1997). The 
conversion from active PAI-1 to its latent form involves incorporating this surface-
exposed loop containing the reactive center into the central β-sheet of the protein 
(Lawrence et al., 1994; Mottonen et al., 1992).  ORM, one of the major acute phase 
proteins, can interact with PAI-1 and stabilize its inhibitory activity toward 
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plasminogen activators (Boncela et al., 2001). The ORM-PAI-1 co-localization was 
found in thymosin β4 (Tβ4)-activated but not in quiescent HUVECs. 
Figure 15: Schematic presentation of uPA and its interacting partners. uPA consists of a serine 
proteinase domain (SPD), a linker, a kringle (K), and a uPAR-binding epidermal growth factor-like 
domain (E). uPAR has three domains and is anchored to the membrane by a GPI anchor. Domains 1 
and 3 make contact with uPA. Plasmin has a serine proteinase domain (SPD) and five kringles (K) 
and binds to pericellular proteins with C-terminal lysines. The RCL of PAI-1 is able to bind to the active 
site of uPA. Vitronectin, in the substratum, has an N-terminal PAI-1- and uPAR-binding somatomedin 
B domain (SomB) next to an integrin-binding RGD sequence. α and β integrin subunits have 
transmembrane helices (TM) and are anchored to the cytoskeleton. Integrins can interact with uPAR 
(Andreasen et al., 2000). 
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2 The aim of study 
 
The aim of this study was: (i) to analyse the whole pattern of urine proteins present in 
urine samples of healthy persons in comparison to that of patients with bladder 
cancer, and to find out the potential relation between urine proteomics and bladder 
cancer stages. (ii) to explore the potential effect of ORM, as one of urinary proteins 
found as an increase amount in urine of patients with bladder cancer, in vascular and 
capillary morphogenesis. (iii) to study potential effect of the interaction between ORM 
and PAI-1 in angiogenesis and capillary morphogenesis. 
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3 Material and Methods 
 
3.1 Materials 
 
3.1.1 Chemical and Consumables 
Acetonitril       Sigma (Taufkirchen) 
Acrylamide      Serva (Heilderberg) 
Agarose        PeqLab (Erlangen)  
Ampicillin       Sigma (Taufkirchen) 
APS        Merck (Darmstadt) 
Bovine Trypsin      Sigma-Aldrich (Steinheim) 
Bench Mark Prestained Protein Ladder Invitrogen (Groningen, Holland) 
CHAPS       Sigma (Taufkirchen) 
Collagen, PureCol     Inamed (Nutacon,Finnland) 
Coomassie Brillant Blue G-250   BioRad (München) 
DMEM        Gibco BRL (Karlsruhe)  
DMSO        Merck (Darmstadt)  
DTT         BioRad (München) 
Ethidiumbromide      Serva (Heidelberg)  
FCS        Gibco BRL (Karlsruhe)  
Histomount      ThermoShandon, (Pittsburg, USA) 
Iodacetamide      Sigma (Taufkirchen)  
LB Agar       Sigma (Taufkirchen) 
L-Glutamin       Gibco BRL (Karlsruhe)  
Nonidet (NP-40)     Calbiochem (Darmstadt) 
MEM        Gibco BRL (Karlsruhe)  
Normal Swine Serum (NSS)   Dako, (Hamburg) 
Normal Rabbit Serum (NRS)   Dako, (Hamburg) 
Nitrocellulose-Membrane    Schleicher & Schuell BioScience (Dassel) 
Oligonucleotides (Primer,siRNA)   MWG Biotech (Ebersberg)  
PBS Dulbecco      Seromed (Berlin)  
Penicillin/Streptomycin     Gibco BRL (Karlsruhe)  
Protease Inhibitor Cocktail    Sigma (Taufkirchen) 
Röntgenfilms      KodakX-AR5 Kodak (Stuttgart)  
Silvernitrate Solution     Sigma (Taufkirchen) 
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SDS-PAGE marker wide range   Sigma (Taufkirchen) 
T4 DNA Ligase      New England Biolabs (Schwalbach/Taunus) 
TBP        BioRad (München) 
TEMED       Sigma (Taufkirchen) 
Thiourea       Sigma (Taufkirchen) 
Triton X-100      Sigma (Taufkirchen) 
Trypsin/EDTA (1x)      Gibco BRL (Karlsruhe)  
Urea        Sigma (Taufkirchen) 
Mowiol        Calbiochem (Darmstadt)  
Cell culture flasks, plates, and tubes   Falcon (Heidelberg)  
Cryo-Save1 (conservation medium)  C.C.pro (Neustadt) 
Unless otherwise stated chemicals and consumables were purchased from following 
companies: Amersham Biosciences (Freiburg), BioRad (München), Biozym 
(Hameln), Invitrogen (Groningen, Holland), Roche (Mannheim), Merck (Darmstadt), 
New England Biolab (Schwalbach/Taunus), Promega (Heidelberg), Roche 
(Mannheim), Roth (Karlsruhe), Serva (Heidelberg) and Sigma-Aldrich (Taufkirchen). 
3.1.2 Kits 
Avidin-Biotin Complex (ABC) kit  Vector (USA) 
BCA Protein Assay Kit Pierce (USA)  
RNeasy Mini Kit  Qiagen (Hilden)  
ECL Plus Western Blotting Detection Kit Amersham Biosciences (Freiburg) 
Silencer siRNA Construction Kit Ambion (Darmstadt) 
HMVEL-L Nucleofector Kit Amaxa-Biosystem (USA) 
TOPO TA Cloning kit Invitrogen (Groningen, Holland) 
Nucleospin® Plasmid Kit Macherey-Nagel (Düren) 
EndoFree Plasmid Maxi Preparation Kit Qiagen (Hilden) 
Gel Extraction Kit Qiagen (Hilden) 
GFX PCR DNA and Gel Band Purification Kit Amersham Bioscience (Freiburg) 
Microcon YM-10 Centrifugal Filter Unit Millipore/Amicon (Bedford, USA) 
Centricon YM-10 Centrifugal Filter Unit Millipore/Amicon (Bedford, USA) 
ReadyPrep Sequential Extraction Kit BioRad (München) 
IPG Strips (11,17 cm) pH 3-10 BioRad (München) 
Criterion Precast Gel BioRad (München) 
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3.1.3 Stock Solutions and Buffers 
Standard media and stock solutions were prepared according to standard procedures 
using deionised water. Solutions were sterilised by autoclaving (25 min/ 121ºC/ 2 
bars). Heat sensitive components were prepared as stock solutions, filter-sterilised 
(0.2 μm) and added to the medium/buffer after cooling to 50ºC. 
 
5x SDS-PAGE Running Buffer (TGS Buffer) 
Tris-HCl   125 mM 
Glycin   960 mM 
SDS    0.5% (w/v) 
 
2D-PAGE Rehydration Buffers: 
 
Reagent 3 (ReadyPrep Sequential Extraction Kit) 
Urea    5 M 
Thiourea   2 M 
CHAPS   2% (w/v) 
SB 3-10   2% (w/v) 
Tris    40 mM 
Biolyte 3-10  2% (v/v) 
TBP(fresh)  2 mM 
DTT(fresh)  0.5% (w/v) 
Bromphenolblue trace 
 
Reagent 2 (ReadyPrep Sequential Extraction Kit) 
Urea    8 M 
CHAPS   4% (w/v) 
SB 3-10   2% (w/v) 
Tris    40 mM 
Biolyte3-10  0.2% (v/v) 
TBP (fresh)  2 mM 
DTT (fresh)  0.5% (w/v) 
Bromphenolblue trace 
 
2D-PAGE Equilibration Buffer I   2D-PAGE Equilibration Buffer II 
Urea    5 M     Urea    5 M  
SDS    20% (w/v)   SDS    20% (w/v) 
Tris-HCl (pH 8.8) 1.5 M   Tris-HCl (pH 8.8) 1.5 M 
Glycerol   50% (w/v)   Glycerol   50% (w/v) 
DTT(fresh)  0.5% (w/v)  Iodacetamid(fresh) 2.5% (w/v) 
 
Fixer Solution I for gel staining   Fixer solution II for gel staining 
Methanol   50% (v/v)    Methanol   5% (v/v)  
Acetic acid  10% (v/v)   Acetic acid  7.5% (v/v) 
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Developer Solution      Coomassie Staining Solution 
Sodiumcarbonate  6% (v/v)  Coomassie BB G-250 0.1% (w/v) 
Formaldehyde   6 mM  (NH4)2SO4   8% (w/v) 
        H3PO4    2% (v/v) 
 
5x Laemlie Protein Loading Buffer  RIPA Lysis Buffer 
Tris-HCl (pH 6.8)  50 mM  Tris-HCl (pH 7.4)  50 mM 
Glycerol    30% (v/v)  NaCl     150 mM 
SDS     4% (w/v)  NP-40    1% (v/v) 
Bromphenolblue  0.5% (w/v) EDTA    1 mM 
DTT (fresh)   0.1 M  SDS (fresh)   0.1% (w/v) 
        Protease Inhibitor cocktail (fresh) 
 
Triton X-100- SDS Lysis Buffer   10x Blotting Buffer 
Triton X-100   1% (v/v)   Tris-HCl    1 M  
SDS     1% (w/v)  Glycin    1.93 M 
 
10x TBS Buffer, pH 7.6    TBS-T Buffer  
Tris-HCl    200 mM  1x TBS (pH 7.6) 
NaCl     1.37 M  Tween-20    0.1% (v/v) 
SDS     0.5% (w/v) 
 
SDS Polyacrylamide Gels 
Stacking Gel (4%): Tris; pH 8.8 1.5 M Running Gel (12%): Tris; pH 6.80 5 M  
SDS   4%      SDS   4% 
 
Stripping Buffer      RNA/DNA-Loading Buffer 
Tris-HCl (pH 6.7)  62.5 mM  Bromphenolblue  0.4% (w/v) 
β-Mercapthoethanol  100 mM  Xylencyanol   0.4% (w/v) 
SDS     2% (w/v)  EDTA     1 mM 
        Glycerin    50% (v/v) 
 
TFB1 (pH 5.8)      TFB2 (pH 6.8 by KOH) 
RbCl     100 mM  MOPS    10 mM 
MnCl2    50 mM  RbCl     10 mM 
Potassium acetate  30 mM  CaCl2    15 mM 
CaCl2    10 mM  Glycerol    15% (v/v) 
Glycerol    15% (v/v) 
 
0.1 M PBS (pH 7.4)     0.1 M PB (pH 7.4) 
Na2HPO4    0.2 M  KH2PO4    0.018 M 
NaCl     0.2 M  Na2HPO4.2H2O   0.082 M 
 
Antibody dilution buffer (PBS/ BSA/ NaN3)  50x TAE  Buffer (pH 7.5) 
0.1 M PBS (pH 7.4)     Tris-Base    2 M  
BSA     0.2% (w/v) Glacial acetic acid  5.7% (v/v) 
NaN3    0.1% (w/v) EDTA    50 mM 
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Glucoseoxidase solution (for 50 ml) 
PB 0.1 M (pH 7.4)   45 ml 
DAB 0.063 M    1 ml 
NH4Cl 3.35 M    100 µl 
NiSO4  0.05 M    900 µl 
Glucose (10%)    900 µl 
Glucose-oxidase 179 U/ml 150 µl 
 
Collagen Gel Mixture (for 10 ml) 
Sterile water    3.95 ml 
10x MEM Medium   1 ml 
L-Glutamin 200 mM   100 µl 
Sodiumpyruvate 100 mM  100 µl 
Collagen      4 ml 
Sodium bicarbonate (7.5%) 500 µl 
Sodium hydroxyle 0.1 M  40 µl 
3.1.4 Equipment and Applications 
Nucleofector: Amaxa., BioSystems 
Cameras: ProgResTMC10plus, Jenoptik 
Microscopes: Phase contrast microscope (Zeiss, Jena); Axiovert 25 (Zeiss, Jena); 
SM-Lux (Leitz) 
Centrifuges: 5415D Centrifuge (Eppendorf) 
Incubator: Hera Cell 240 (Thermo) 
PCR-Thermocycler: T3000 Thermocyler (Biometra) 
Photometer: UV-Spectrometer, SmartSpec 3000 (BioRad) 
MALDI-TOF spectrometer: Axima CFR (Shimadzu Biotech) 
Gel electrophoresis and electroblotting equipment: Criterion Dodeca Cell, Protean 
IEF Cell, Disposable Rehydration/Equilibration Tray (BioRad), Mini protean and 
Trans-Blot-System (BioRad). 
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3.1.5 Antibodies 
Antibody Source Working dilution Supplier 
Anti-Alpha1 acid glycoprotein 
(AGP) Rabbit 1:200 Dako, Hamburg  
Anti-Zinc Alpha Glycoprotein(ZAG) Goat 1:200 Santa Cruz, USA 
Vimentin Mouse 1:1000 Dako, Hamburg 
Table 4: Primary antibodies used for western blot and Immunohistochemistry 
Antibody Working dilution Supplier 
Anti-mouse IgG 1:8000 Sigma, Taufkirchen 
Anti-rabbit IgG 1:30,000 Sigma, Taufkirchen 
Anti-goat IgG 1:30,000 Sigma, Taufkirchen 
Table 5: Secondary HRP antibodies used for western blot 
3.1.6 Cell lines and medium for cultivation of cell lines 
Unless purchased sterile, all media, solutions and supplements used in cell culture 
work were sterilised with a 0.2 µm filter, strored at 4°C and prewarmed to 37°C prior 
to use. 
Cell Lines Characteristics Source 
HDMECs Human Dermal Microvascular Endothelial Cells (HDMECs) derived from dermis PromoCell, Heildelberg 
RT4 Human Bladder Cancer Cells 
Obtained from Department of 
Urology, University Hospital 
Hamburg-Eppendorf 
 
Table 6: Used cell lines 
 
Cell Lines Medium 
HDMECs 
Endothelial Cell Growth Medium MV (PromoCell): After adding the 
SupplementMix, the concentrations of growth factors are; 0.4% ECGS/H; 
5% Fetal Calf Serum; 0.1 ng/mL Epidermal Growth Factor; 1µg/mL 
Hydrocortison; 1ng/mL basic Fibroblast Factor 
RT4 McCoy’s Medium (Gibco,USA): 10% Fetal Calf Serum; 1% Glutamine; 1% penicillin/ streptomycin  
 
Table 7: Cultivation medium for cell lines 
3.1.7 Bacterial strains 
For cloning applications, the E. coli strains DH5α and XL1-Blue were used. Ligation 
reactions were transformed into XL1-Blue strain; plasmids requiring digestion with 
methylation sensitive restriction enzymes were transformed into DH5α strain. PCR 
products were cloned using the TOPO TA cloning kit (Invitrogen) with the supplied 
Top10F' bacteria. 
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Strains Genotype Source 
 
DH5α F'  φ80lacZ∆M15 ∆(lacZYA-argF)U169 deoR recA1 endA1 hsdR17(rk-,mk+) phoA supE44 ג- thi-1 gyrA96 
relA1 
Invitrogen (Groningen, 
Holland) 
 
XL1-Blue 
recA1, endA1, gyrA96, thi-1, hsdR17, supE44, relA1, 
lac {F',  proAB, lacIqZΔM15, Tn10(TetR)} Stratagene(Heildelberg)
Top10F' 
F- {lacIq Tn10 (TetR)} mcrA ∆(mrr-hsdRMS-mcrBC) 
φ80lacZ∆M15 ∆lacX74 recA1 araD139 ∆(ara, leu)7697 
galU galK rpsL (StrR) endA1 nupG 
Invitrogen (Groningen, 
Holland) 
Table 8: Bacterial Strains. Names, genotypes and suppliers of the bacterial strains used. 
3.1.8 Primers 
Oligonucleotides used for PCR and contruction of siRNA were purchased from MWG 
Biotech. 
 
Primer 
Name Line Sequence ( 5→3 ) 
Genbank 
Number Tm (°C) 
PCR cycle 
numbers 
Forward  ACGTGCCTCCTGGTCTCAGTA 62.1  ORM 
 Reverse  TTAGCTGTTCCAAACACAGAAG NM_00067 56.5 35 
Forward TGATGACATCAAGAAGGTGG 55.3 GAPDH Reverse TTTCTTACTCCTTGGAGGCC NM_002064 57,3 35 
  
Table 9: Oligonucleotides used for in PCR 
 
Primer Name Line Sequence ( 5→3 ) Tm (°C) 
sense AAGACTTATTGTACTCCTCGTCCTGTCTC 65.3 siRNA ORM 
TS231 antisense AAACGAGGAGTACAATAAGTCCCTGTCTC 65.3 
sense AATGAAGTAAAAGAAGGTTGCCCTGTCTC 63.9 siRNA ORM 
TS266 antisense AAGCAACCTTCTTTTACTTCACCTGTCTC 63.9 
sense AATCGAAGTATTCCGCGTACGCCTGTCTC 55,3 siRNA 
Luciferase antisense AACGTACGCGGAATACTTCGACCTGTCTC 55,3 
  
Table 10: Oligonucleotides used for in siRNA construction 
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3.1.9 Urine samples 
 
Spontaneous urine samples of 45 patients with bladder cancer of different stages 
(pTa, pT1, pT2-3, GI, GII, GIII), patients on follow-up and healthy volunteers were 
collected and after centrifugation at 5000 rpm for 5 min stored at –20°C (for a longer 
time than 2 months at –80°C) until their use. 
 
Bladder Cancer Patients (n=45) 
pTa (n=12) PT1(n=8) PT2-3(n=8) 
Age, 60-80      Age, 60-80 Age, 60-80 
Female, n=7 Female, n=2 Female, n=1 
Male, n=5 Male, n=6 Male, n=7 
GI, n=4 GI, n=1 GIII, n=8 
GII, n=8 GII, n= 3  
 GIII, n=4  
 
 Patients on follow-up (n=10) Healthy Volunteers (n=7) 
Age 60-80 30-50 
Female n=4 n=3 
Male n=6 n=7 
  
Table 11: Urine samples used in 2-DE analyses and western blotting 
 
3.1.10   Tissue samples 
Tissue samples were provided from the Department of Pathology of the University 
Hospital Hamburg-Eppendorf. Normal tissue samples from human bladder were 
obtained by biopsy or by cystoprostatectomy because of prostate cancer, and tumor 
tissues of bladder cancer were obtained from patients who had undergone surgical 
therapy. The determination of tumor stage was made by the Department of 
Pathology according to the WHO (World Health Organization) classification. The 
tissue blocks were fixed in formaldehyde and embedded in paraffin and subsequently 
sectioned for use in immunohistochemistry. 
 
3.2 Methods 
3.2.1 Protein analyses 
3.2.1.1 Determination of total protein 
The concentration of proteins was determined by BCA protein assay kit which is 
based on bicinchoninic acid (BCA) for the colorimetric detection and quantitation of 
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total protein. The complex giving colour exhibits a strong absorbance at 562 nm. BSA 
(Bovine Serum Albumin) was also serially diluted and used as standard. 2 ml of the 
BCA working reagent mix was added to each sample and to standard tubes. After a 
short vortex the tubes were incubated at 37°C for 30 min. For each dilution, 
measurements were performed in duplicate and the average was taken for the 
calculation of the protein concentration. 
 
3.2.1.2 Two dimensional polyacrylamide gel electrophoresis (2D-PAGE) 
 
Two dimensional gelelectrophoresis separates protein mixtures due to differences in 
their isoelectric point (pI), in the first dimension and subsequently by their molecular 
weight (MW) in the second dimension represented in figure 16. 
 
 
Figure 16: Schematical representation of two dimensional separation. Proteins are separated in 
two dimensions horizontally by iso-electric point (pI) and vertically by molecular weight (MW). 
 
3.2.1.3 Preparation of urine samples for 2-DE 
 
After protein determination, urine volume containing 200 µg total protein was applied 
onto a Centrifugal Filter Column (Amicon) to remove molecules smaller than 10 kDa 
such as urea, electrolytes, salts and to increase the protein concentration of the urine 
samples. The centrifugal column containing urine volume was centrifugated at speed 
linearly increased from 3000 rpm to 6000 rpm at 4°C until complete urine volumes 
were filtered through the filter membrane. Remained protein molecules were washed 
with 50 µl distilled water and centrifugated at 6000 rpm for 30 min. Filtered urine 
samples were diluted in rehyration buffer 2 (3.1.3). After fresh adding of TBP, DTT 
and trace of bromophenolblue, protein lysates were centrifugated at 15,000 rpm for 
10 min at 4°C to remove insoluble particles. Supernatant containing urinary proteins 
was used for sample loading step of 2-DE procedure. 
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IPG Strip Length / pH Range Loaded protein amount 
11 cm, pH 3-10, nonlinear (NL) 200 µg (in 200 µl volume) 
17 cm, pH 3-10, Linear (L) 300 µg (in 300 µl volume) 
  
Table 12: IPG strips used for 2-DE analyses 
 
Additionally, TCA (tricholoroaceticacid) precipitation was performed on the urine 
samples to precipitate all proteins present in urine. Shortly, an equal volume of 20% 
TCA were added to the urine samples and incubated on ice for 30 min. After 
centrifugation at 13,000 rpm for 10 min at 4°C, the supernatant was removed and 
protein pellets were diluted in rehydration buffer2-3 (3.1.3). But, this method was not 
effective for 2-DE analysis; it led to vertical streaks due to remained TCA particles 
(data was not shown). To precipitate a specific protein present in urine, 
immunoprecipitation was performed on urine samples. However, the 2-DE results of 
immunoprecipitated samples were not informative due to remained IgG 
(Immunglobulin G) coming from secondary antibody (data was not shown). Therefore 
ultracentrifugation was used for all urine samples prior their use in 2-DE process. 
 
3.2.1.4 Rehydration 
 
The PROTEAN IEF cell with integrated power supply was used for rehydration and 
IEF protocols. Diluted protein samples were loaded onto IPG strips in IEF focusing 
tray for rehydration and first dimensional separation. IPG strip gels were placed side 
down in the channel of a focusing or rehydration tray that contains the sample in 
rehydration solution. For urine samples mostly 11 cm nonlinear IPG strips with 3-10 
pH range were used and  for a large scale of gel the strips with 17 cm length were 
used (Tab. 12). Strips were covered with 2 ml of mineral oil to prevent evaporation 
which causes the urea to precipitate as it becomes more concentrated. IPG strips 
with sample in a focusing tray were active rehydrated by running of IEF cell under 
low voltage as 50 V overnight. 
 
3.2.1.5 First dimensional separation: Isoelectric focusing (IEF) 
 
After the strips have rehydrated the ends of each strip was lifted and wet electrode 
wicks were inserted between the strip and the electrodes. Strips were covered with 
mineral oil before starting the focusing run to prevent evaporation and carbon dioxide 
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absorpsion during focusing. Isoelectric focusing was performed at voltage linearly 
increased from 250 to 5000 V during the first 5 h, followed by 8000 V for a total of 
70000 Vh/h (Tab. 13). 
 
Temperature 20˚C 
Current max. 0.05 mA per strip 
Sample volume 200 µl for 11 cm strip, 300 µl for 17 cm strip  
 
Step Voltage Time / Volt-hour 
1 150 V 30 min. rapid 
2 300 V 60 min. slow 
3 1000 V 60 min. slow 
4 1500 V 60 min. slow 
5 2000 V 60 min. slow 
6 3000 V 60 min. slow 
7 5000 V 60 min. slow 
8 8000 V 4 h slow 
9 8000 V 70,000 Vh linear 
10 500 V 3 h linear 
  
Table 13: Applied voltage steps for IEF 
 
3.2.1.6 Equilibration 
 
This process reduces disulfide bonds and alkylates the resultant sulfhydryl groups of 
the cysteine residues. Rehydration/equilibration trays sized for each size strip were 
used for equilibration. Each strip was moved to equilibration tray and the channels 
were filled with the equilibration buffers. Strips were first incubated in DTT 
equilibration buffer-I (3.1.3) that reduces sulphydryl groups for 15 min at RT, than the 
channels were refilled with iodacetamide equilibration buffer-II (3.1.3) which alkylates 
sulfhdryl groups and incubated for 15 min at RT. For the strips with 11 cm length, 3 
ml of each equilibration buffer and for the strips with 17 cm length 5 ml of each 
equilibration buffer were used. After equilibration, IPG strips were removed and 
embed into the prepared second-dimension gel. 
 
3.2.1.7 Second dimensional separation 
 
The second dimension electrophoresis of isoelectric focused proteins was carried out 
on pre-prepared polyacrylamide gels obtained from BioRad (Criterion Precast Gel 
10% Tris-HCl, 1.0 mm). The equilibrated IPG gel strips were placed on top of the 
polyacrylamide gel and overlaid with 2 ml 0.5% melted agarose prepared in SDS-
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PAGE running buffer. A small amount of Bromophenolblue was added to the agarose 
overlay to track the ion front during the run. The SDS gel running was performed with 
a voltage setting of 120 V for 45 min and 150 V for 20 min. BioRad Dodeca Cell 
which accommodate 12 gels per run was mostly used for proteomics analyses. To 
estimate the molecular mass of each spot, marker proteins (SigmaMarkerTM, wide 
molecular weight) were placed on a filter strip left to the strip on the gel. 
Polyacrylamide gels were stained with silver and/or Coomassie Brillant Blue (BioRad) 
according to the procedures described previously (Merril et al., 1981). 
 
3.2.1.8 Protein detection 
 
To visualize proteins after separation in 2-DE gels it is necessary to use an adequate 
staining method. The enormous variation in characteristics and abundance of the 
individual proteins put high demands on the staining technique. The most important 
requirements are high sensitivity, high linear dynamic range, high reproducibility and 
compatibility with mass spectrometry. Major developments of protein staining 
methods have occurred during the last few years. Since silver staining is the most 
sensitive non-radioactive detection technique and the costs for reagents are relatively 
low when compared to fluorescence techniques, it is still widely used. There are 
presently more than 100 different modifications of the original silver staining protocol 
that was introduced by (Merril et al., 1981). In this study silver staining and 
coomassie blue staining methods were used to visualize the protein spots. 
 
3.2.1.9 Silver staining 
 
After second dimensional separation the gels were taken out and incubated first with 
fixer solution-I (3.1.3) containing 50% methanol and 10% acetic acid for 30 min 
following second incubation with fixer solution-II (3.1.3) containing 5% methanol and 
7.5% acetic acid for 10 min at RT. After fixation, the gels were washed twice with 
distilled water for 5 min at RT on a shaker. Gels were then incubated with 0.002% 
sodiumthiosulphate for 1 min and washed twice with distilled water for 1 min. For 
staining, fresh prepared 0.2% silver nitrate solution was used. The gels were 
incubated with silver nitrate solution in dark for 30 min at RT. After a washing step as 
2x1 min, the gels were incubated with fresh developer solution (3.1.3) containing 6% 
sodium carbonate and 6 mM formaldehyde for 5-20 min until the protein spots 
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became visualized. A few solid citric acid particles were added to stop the 
development of the gels. After washing, gels were scanned for the image analysis. 
 
3.2.1.10 Coomassie staining 
 
For coomassie staining, the gels were incubated with fixer solution-I (3.1.3) for 30 
min at RT on a shaker. After washing twice with distilled water for 5 min, gels were 
stained by incubation using coomassie solution (3.1.3) for overnight. Stained gels 
were washed several times with distilled water to remove remained coomassie 
crystals and excess dye from gel. 
 
3.2.1.11 Image and data analysis 
 
The resulting 2-DE images were analysed using PDQuest software programme 
(BioRad). Gel analysis includes spot detection, spot quantitation, gel comparison, 
and statistical analysis. Before the software automatically detected the protein spots 
of a 2-DE gel, the raw image data were corrected and background was subtracted. 
 
3.2.1.12 Mass spectrometry and bioinformatics 
 
Some of the visible protein spots on the stained gels have been identified by mass 
spectrometric analysis in Heinrich-Pette-Institute of Hamburg University. Coomassie 
Brilliant Blue-stained protein spots (Coomassie G250) were excised, cut in 1 mm3 
pieces, washed twice with distilled water and destained with 50% v/v acetonitrile 
(MeCN) in 25 mM ammonium bicarbonate for 2x15 min, shrunk by dehydration in 
acetonitrile for 15 min, and dried in a vacuum centrifuge for 10 min. The gel pieces 
were reswollen in 10-20 µl of 25 mM ammonium bicarbonate, containing 200-400 ng 
of bovine trypsin (proteomics sequencing grade; Sigma-Aldrich) at 4°C. After 60 min, 
10-20 µl of 25 mM ammonium bicarbonate were added if necessary to keep the gel 
pieces wet during tryptic cleavage (37ºC, overnight). The peptides were extracted 
sequentially with water, 0.1% TFA, 10% MeCN/0.1% TFA, 20% MeCN/ 0.1% TFA 
and 40% MeCN/0, 1% TFA for 30 min each. The separated liquids were combined 
and dried under vacuum. The peptides were redissolved in 4 µl matrix solution 
containing 10 mg dihydroxybenzoic acid, 5 mg diammonium hydrogen citrate, 0,1% 
TFA, and 0,05% phosphoric acid in 50% MeCN. For MS-analysis 1 µl were spotted 
onto the target plate and air-dried. MALDI-MS measurements were performed on an 
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Axima CFR MALDI-TOF spectrometer (Shimadzu Biotech) in positive mode with 
reflectron, delayed extraction was optimized for 2500 mu. Dependent on spectra 
quality 200-400 laser shots were accumulated. Control of the spectrometer and 
spectra processing was done with the Axima CFR software V2.2.1.  Mass spectra 
were calibrated using known autolytic fragments of trypsin, Angiotensine III and 
acetylated Insulin B chain as internal standards. The peptide masses were measured 
as monoisotopic masses. 
 
Native Urine 
Centrifugation and
Filtration 
Separation of urinary proteins
2-DE
Identification of proteins
Mass Spectrometric analyses
Detection of protein spots
(Coomassie / Silver staining)
 
 
Figure 17: Experimental flow diagram. This diagram shows the experimental steps of analyses of 
urine samples. Native urine containing a certain amount total protein was centrifugated and filtrated. 
After first and second dimensional separation using 2-DE technique, the 2-DE gels were stained using 
silver and/or coomassie blue staining protocol to visualize protein spots. The spots of interest were cut 
out from gel and identified by mass spectrometric analyses. 
 
Proteins were identified by searching the NCBI database using the program 
MASCOT (Matrix Science; http://www.matrixscience.com/serach_form_select.html). 
The parameters for the search were as follows: the modifications acetamide on 
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cysteine residues and methionine oxidation were considered as a partial modification 
and three was used as the maximum missed tryptic cleavage sites. 
 
3.2.1.13 SDS-polyacrylamide gelelectrophoresis 
 
One dimensional gel electrophoresis (Laemmli, 1970) under denaturing conditions (in 
presence of SDS) was used for separation of the proteins on the base of their 
molecular size. The polyacrylamide gel was prepared as a separating gel (sometimes 
called resolving or running gel) topped by a stacking gel and secured in an 
electrophoresis apparatus from BioRad. After sample proteins are solubilised by 
boiling in the presence of SDS, an aliquot of the protein solution is applied to a gel 
line, and the individual proteins are separated electrophoretically. The mobility of the 
proteins is inversely proportional to the logarithm of their molecular mass. SDS is 
employed to effect denaturation of the proteins, to dissociate protein complexes and 
to impart upon the polypeptide chains net negative charge densities proportional to 
the length of the molecule. A reducing agent as DTT was used to reduce any existing 
disulphide bond. After one dimensional separation the proteins was detected using 
staining methods which is able to detect all proteins and by immunoblotting for 
detection of a specific protein. 
 
3.2.1.14 Western blotting 
 
Electroblotting of proteins from polyacrylamide gels onto retentive membranes was 
performed for immunoblotting following detection of accumulated proteins using a 
specific antibody. Proteins were separated by SDS-PAGE and electrophoretically 
transferred from the polyacrylamide gel to a nitrocellulose membrane at 350 mA 
constant current for 1 hour. 
Proteins were separated on 12% SDS-Acrylamide gel which was prepared according 
to the „Mini Protean Manual Instruction’ from BioRad. For preparation of gels 30% 
acrylamide solution obtained from Serva was used. 25 µl of different protein samples 
containing 50 µg total protein were denaturated by adding of sample loading buffer 
(3.1.3) including DTT and following heating at 95ºC for 5 min. Protein samples were 
loaded onto the gel and running was performed at 120 volt for 90 min. Prestained 
protein marker from invitrogen was used to estimate molecular size of separated 
proteins. For transferring of proteins from SDS gel to nitrocellulose membrane, 
equipment as “Mini Trans-Blot-System“ obtained from BioRad was used according to 
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the manufacturer’s recommendations. For blotting nitrocellulose membranes 
(Schleicher & Schuell, BioScience) were cut in size as 7x9 cm and wetted by transfer 
buffer shortly before placing. The fiber pads and filter papers were pre-wetted with 1x 
Transfer buffer. Gel containing proteins and nitrocellulose membranes were allowed 
to contact by a sandwich model placing in order as a fiber pad, a filter paper, gel, 
nitrocellulose membrane, a filter paper, a fiber pad (from cathode plate to anode 
plate). The cassettes were placed in the chamber and a cold pack was put beside 
and filled with pre-chilled 1xTransfer buffer (3.1.3). Electrophoretically transfer was 
performed 1 h at 350 mA current on a stir plate. After the transfer onto nitrocellulose, 
the blots were taken out and washed with distilled water. To prevent unspecific 
bindings, blots were incubated with blocking buffer containing 5% non-fat milk 
solution in 1xTBS-T buffer (3.1.3) overnight at 4ºC. Next day the blots were incubated 
with the primary antibody in 1xTBS-T solution for 1 h at RT. After 2x10 min washing 
in 1xTBS-T buffer the membranes were incubated for 1 h at RT with the horseradish 
peroxidise-coupled secondary antibody in blocking buffer. Finally, the membranes 
were washed 2x10 min and 2x20 min with 1xTBS-T buffer. The antigen-antibody 
complex was detected by enhanced chemiluminescence using ECL reagents 
(Amersham-Pharmacia) and visualized by auroradiography. The X-ray films were 
digitalized for subsequent densitometric quantification of the bands using the 
morphometric program OptimasTM (Seattle, USA). 
3.2.2 Molecularbiological methods 
3.2.2.1 Cultivation and storage of E. coli 
 
Bacteria were cultivated in Luria-Bertani (LB)-broth or on LB-agar plates at 37°C. For 
selection of transformed bacteria, broth and plates were supplied with 50 mg/l 
ampicillin. 
Freshly plated bacteria were viable for approximately one month when stored at 4°C. 
For long-term storage, glycerol stocks were prepared by mixing 500 µl of an 
overnight liquid culture with 500 µl of 15% sterile glycerol. The stocks were stored at 
–80°C. 
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3.2.2.2 Preparation of competent cells 
 
DH5-α bacterial were obtained from Invitrogen and competent E. coli cell stocks were 
prepared using protocol described previously (Sambrook, 1989) 200 µl of DH5-α cells 
were thawed on ice and were mixed with 10 ml LB-medium without antibiotic. After 
overnight incubation at 37°C with shaking at 225-250 rpm, 200 µl of mixture were 
plated on an agar plate without antibiotic and incubated overnight at 37°C. A single 
colony was picked and 10 ml LB medium was inoculated with. After overnight 
incubation at 37°C, 1 ml of overnight culture was added to 100 ml pre-warmed LB 
medium without antibiotic. The culture was incubated and shaked at 37°C until an 
OD600 OF 0.5 was reached (approximately 90-120 min). The culture was cooled on 
ice for 5 min and transferred to a sterile round-bottom centrifuge tube. The cells were 
collected by centrifugation at low speed (5 min, 1500 rpm, 4°C). After supernatant 
was removed, the cells were resuspended in cold TFB1 buffer (3.1.3) (30 ml for a 100 
ml culture) and suspension was incubated on ice for 90 min., followed centrifugation 
for 5 min at 1500 rpm at 4°C. The cells were resuspended in 4 ml ice-cold TFB2 
buffer (3.1.3). Aliquots of 100 µl in sterile microcentrifuge tubes were prepared and 
frozen in liquid nitrogen. The competent cells were stored at -80°C. 
 
3.2.2.3 Bacterial transformation 
 
Bacterial transformation which is needed for cloning application was performed using  
E. coli strains DH5α and XL1-Blue (Tab. 8). 50 µl of competent cells were thawed on 
ice. 1-5 ng purified DNA or 1-5 µl of ligation reaction was added to one aliquot of cells 
and mixed by pipetting. The tubes containing cells and DNA were incubated on ice 
for 30 min, and then were heat-pulsed in a 42°C water bath for 45 seconds, followed 
incubation on ice for 2 min. After adding 500 µl pre-warmed LB medium to each 
sample, the tubes were incubated at 37°C for 1 hour with shaking at 225-250 rpm. 
After incubation 50-500 µl of transformation mixture were spread on LB agar plates 
containing 50 mg/l ampicillin. The plates were incubated overnight at 37°C. Single 
colonies were picked and incubated with LB medium containing ampicillin at 37°C 
overnight with shaking. The plasmid DNA was isolated using either Plasmid Maxi Kit 
(Qiagen) or for further transfection application, EndoFree Plasmid Maxi Kit (Qiagen). 
Transformed bacteria were stored as 1:1 mixture with sterile glycerol stock at –80°C. 
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3.2.2.4 Purification of DNA from solution and gel bands 
 
For isolation and purification of DNA from PCR product and/or agarose gel bands, 
GFX PCR DNA and Gel Band Purification Kit (Amersham Biosciences) was used.  
This kit uses a chaotropic agent that denaturates proteins, dissolves agarose, and 
promotes the binding of double-stranded DNA (100 base-pairs to 48 kilobase-pairs) 
to a glass fiber matrix. Purification of DNA was performed using the protocol provided 
by GFX purification kit. First DNA was denatured and for gel band purification, 
agarose was dissolved. DNA samples were passed through the GFX column 
provided with kit to capture the DNA onto the glass fiber matrix. Then Matrix-bound 
DNA was washed with an ethanolic buffer to remove salts and other contaminants. 
Purified DNA was eluted from GFX column in a low ionic strength buffer (TE pH 8.0, 
10 mM Tris-HCl pH 8.0, or water). 
 
3.2.2.5 Minipreparation of plasmid-DNA 
 
For small-scale preparation of plasmid DNA, Nucleospin® Plasmid Kit (Macherey-
Nagel) was used. Isolation of plasmid DNA was performed according to protocol from 
Nucleospin® Plasmid kit. The pelleted bacteria were resuspended and plasmid DNA 
was liberated from the E.coli host cells by SDS/alkaline lysis. SDS precipitate and 
cell debris were pelleted by a centrifugation step, the supernatant was loaded onto a 
Nucleospin® Plasmid column. Pure plasmid DNA was finally eluted under low ionic 
strength conditions with slightly alkaline buffer (5 mM Tris-Cl, pH 8.5) which provided 
with kit. Concentration of DNA was measured by UV-spectrophotometer. 
 
3.2.2.6 Maxipreparation of plasmid-DNA 
 
For isolation of plasmid DNA in high culture volume, Plasmid Maxi Kit (Qiagen) was 
used. The purification protocol of kit is based on a modified alkaline lysis procedure, 
followed by binding of plasmid DNA to Qiagen Anion-Exchange Resin under 
appropriate low-salt and pH conditions. 100 ml of LB-Medium containing Ampicillin 
was inoculated by a picked single colony from a selective agar plate and then 
cultured by over night incubation at 37°C on a rotation shaker. Plasmid DNA was 
isolated using the protocol from Plasmid Maxi Kit and diluted in 200 µl TE buffer or in 
buffer containing 10 mM Tris-Cl, pH 8.5. DNA concentration was determined by UV 
spectrophotometry and quantitative analysis on an agarose gel. Plasmid DNA which 
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was further transfected into the cells was isolated using EndoFree Plasmid Maxi Kit 
(Qiagen) due to endotoxin effects efficiency of gene transfer. 
 
3.2.2.7 Restriction digest of DNA 
 
Restriction enzymes and appropriate buffers were obtained from NEB. Restriction 
digest and double restriction digest of DNA were performed according to the 
manufacturers' protocol. The general protocol for restriction digestion of DNA is 
shown in table 14. 
    Components           Concentration / Volume 
 
        DNA      1-3 µg 
   Restriction Enzyme   3 U/ µg DNA 
   10x Buffer     2 µl  
   Distilled water    ad 20 µl 
 
Table 14: Composition of restriction digests reaction 
 
After incubation of the reaction mixture at 37°C for 1 h per 5U of restriction enzyme, 
the reaction was inactivated by incubation at 75°C for 20 min. 
 
3.2.2.8 Agarose gel electrophoresis 
 
PCR fragments and/or digested DNA were electrophoretically separated on 1-2% 
(w/v) analytical agarose gels prepared in TAE buffer containing 0.1 g/ml ethidium 
bromide.  
1x TAE buffer (3.1.3) was used as running buffer. DNA samples were mixed with 6x 
loading buffer (3.1.3) and loaded onto the gel. 500 ng of DNA molecular marker 
(Invitrogen) were used for evaluation of sample size and integrity. The DNA was 
visualised on an UV transilluminator at 302 nm and documented by a gel 
documentation instrument (Intas). Interested DNA bands were cut out from agarose 
gel using a sterile scalpel. DNA was isolated from cut gel using GFX PCR DNA kit or 
in some cases Gel Extraction Kit (Qiagen). After isolation and purification, DNA 
samples were electrophoretically separated on agarose gel for controlling. After that, 
DNA concentration was measured by UV-spectrophotometry. 
 
3.2.2.9 Sequencing of DNA 
 
All sequencing of plasmids was performed by MWG Biotech. The sequence data 
were compared using sequence comparing programme, BLAST (Basic Local 
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Alignment Search Tool) in EMBL (European Molecular Biology Laboratory)-Databank 
(http://www.ncbi.nlm.nih/gov/Blast/). 
 
3.2.2.10 Determination of DNA concentration 
 
For determination of DNA concentration SmartSpec3000 UV-Spectrometer (BioRad) 
was used. DNA samples were diluted as 1:100 with distilled water, which used also 
as blank and 100 µl of diluted DNA samples were placed into micro-quartz cuvetes. 
Absorbance was measured for double strand DNA using UV-light by 260 nm 
wavelength. 
 
3.2.2.11 Construction of pcDNA3.1(-)/ORM expression vector 
 
For overexpresssion of ORM in HDMECs via nucleofection technology, the 
expression vector pcDNA3.1(-)/ORM was constructed. For this, the full-length cDNA 
encoding ORM was cloned into the XhoI and HindIII restriction sites of the 
expression vector pcDNA3.1/Hygro(-) (Clontech). Firstly the cDNA encoding for ORM 
gene was amplified by PCR from cDNA of human granulocytes using gene specific 
primers. Subsequently the PCR product was ligated into the 2.1-TOPO® vector. 
 
3.2.2.12 Polymerase chain reaction (PCR) 
 
Polymerase chain reaction (PCR), a procedure for rapid in vitro enzymatic 
amplification of a specific segment of DNA, was used for the amplification of cDNA 
encoding ORM. cDNA of granulocytes which obtained as a gift from the Department 
of Clinical Chemistry of University Hospital Hamburg-Eppendorf, was used directly as 
a template for PCR to amplificate ORM genes present in granulocytes. 
 
    Components          Concentration / Volume 
 
        DNA      1 µl 
   dNTP      10 mM 
   MgCl2     50 mM 
   Primer     20 pmol each 
   Taq DNA polymerase    1 U 
   10xPCR Buffer    1x 
   Distilled water    ad 25 µl 
 
Table 15: Composition of PCR reaction 
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                            Step                        Temperature [°C]           Time 
 
         Initial denaturation  95    10 min 
     35 Cycles: 
     Denaturation   95    45 sec 
     Primer annealing  60    45 sec 
     Elongation    72    1 min 
     Final elongation   72    10 min 
 
Table 16: PCR conditions for ORM 
 
The reactions were performed in 0.2 ml PCR tubes (Biozym), using a PCR 
thermocycler (MWG Biotech). Specific primers annealing to the vector backbone 
were used for PCR reaction (Tab. 15). GAPDH was used as control reaction. 
Thermocycler conditions were used as described in table 16. The PCR products 
were analysed on a 1% agarose gel (3.2.2.8) and purified using GFX PCR DNA and 
Gel Band Purification Kit (Amersham Biosciences) (3.2.2.4). 
 
3.2.2.13 Ligation of PCR product into pCR® 2.1-TOPO® Vector 
 
The PCR product coding for ORM gene was purified using GFX PCR DNA and Gel 
Band Purification Kit (Amersham Biosciences). For direct insertion of Taq 
polymerase-amplified PCR product into a plasmid vector, TOPO TA cloning Kit 
(Invitrogen) was used. The pCR® 2.1-TOPO® vector provided with kit was used as 
linearized with single 3´-thymidine (T) overhanging  3´-deoxythymidine (T) residues 
which allows PCR inserts to ligate with the vector. 
Insertion of PCR product into the TOPO vector was performed according to 
manufacturer’s protocol provided with kit.  PCR product and TOPO vector were 
mixed and incubated at RT for 5 min. TOPO cloning reaction was transformed into 
chemically competent cells and single colonies were selected to isolate DNA. 
The selected single colonies were cultured in LB-medium overnight and DNA was 
isolated using protocol from Nucleospin® Plasmid kit. After DNA concentration 
measurement, DNA samples were digested at HindIII and XhoI restriction site and 
electrophoretically separated on agarose gel. One of positive clones was selected 
and used for subcloning of TOPO/ORM into the expression vector as next step. 
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3.2.2.14 Subcloning into pcDNA3.1(-) 
 
The pcDNA3.1(-) is 5.4 kb vector designed for high-level stable and transient 
expression in mammalian cells.  The pcDNA3.1(-) expression vector and TOPO/ORM 
plasmid vector were digested at HindIII and XhoI restriction site and after extraction 
of digested pcDNA3.1(-) and ORM insert from agarose gel ligation reaction were 
performed using the T4-Ligase. Ligation reaction was incubated overnight at 16 °C 
and directly transformed into E. coli strains DH5α or XL1. Single colonies on LB-agar 
plates were selected and analysed for the presence of insert by HindIII and XhoI 
restriction digestion. A transformant which has correct restriction pattern was 
selected and sequenced by MWG Biotech to confirm that ORM gene was cloned in 
the proper orientation. 
 
3.2.2.15 siRNA construction 
 
For ORM gene silencing via small interfering RNA (siRNA) the Silencer™ siRNA 
Construction Kit (Ambion) was used.  
 
 
 
Figure 18: Mechanism of gene silencing via siRNA 
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The siRNAs are 21-23 nucleotides double-stranded RNAs, which induce post-
transcriptional gene silencing. After introducing the siRNAs into the cells, they were 
assembled with protein components into a RNA-induced silencing complex (RISC). 
An ATP-generated unwinding of the siRNA activates the RISC, which in turn binds to 
the homologous transcripts by base pairing interaction and cleaves the mRNA. This 
sequence specific degradation of mRNA results in gene silencing (Fig. 18). 
Following target regions for the siRNA sequences are selected from the cDNA of 
ORM according to the guidelines described by Elbashir et al. (Elbashir et al., 2001). 
Target sequence (cDNA) from the firefly luciferase gene was chosen as a control for 
ORM silencing studies. 
3.2.3 Cellbiological methods 
 
General cell culture work was performed under sterile conditions under a laminar flow 
hood using disposable plastic ware. 
 
3.2.3.1 Culturing of cells 
 
Cell lines (Tab. 6) were placed in polystyrene culture flasks 25 cm
2 
(T25) and 75 cm
2 
(T75) (Falcon) provided with 0.2 µm hydrophobic vent caps and maintained in a 
humidified 5% CO2 atmosphere in an incubator (Hera Cell 240) at 37°C. All culture 
media (Tab. 7) were sterilized by filtration. Glass wares were sterilized by heating at 
180°C for 8 h, and plastic wares were autoclaved at 120°C and 1.2 bar for 20 min. 
Adherent cells were cultured until a confluence of 70-90%. Medium was removed 
and after two times PBS washing, the cells were incubated with trypsin for one 
minute at 37°C and the reaction was stopped by addition of double used trypsin 
volume of culture medium. Cell suspension was harvested by centrifugation (1200 
rpm /5 min/ RT). The supernatant was removed and cells were washed by 
resuspension in PBS with subsequent centrifugation. For subculturing cells were 
diluted approximately 1:5 fold with fresh medium. 
 
3.2.3.2 Freezing and thawing of cells 
 
500,000 viable human dermal microvascular endothelial cells (HDMECs) (Tab. 6), 
derived from dermis and cryopreserved in 1ml serum-free freezing medium, after 
thawing were obtained from PromoCell. HDMECs were cultured and passaged until 
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passage four, and then used for experiments. HDMECs were not used after passage 
eight and were also not frozen and stored. For all experiments thawed and viable 
HDMECs were shipped from PromoCell. 
RT4 cells (Tab. 6) were harvested at a concentration of 0,5x106 cells/ml, washed with 
PBS and resuspended in 1 ml ice cold cryo-conservation medium. The cryovials 
(Nunc) with 1 ml cell suspension each were placed in a -80°C freezer and transferred 
to liquid nitrogen for long-time storage. 
Cryopreserved cells were thawed rapidly in a 37°C water bath, transferred to 20 ml 
prewarmed medium and centrifuged (1200 rpm/ 5 min). Supernatant was discarded 
and cells were seeded at high density in culture flasks (25 cm2 and 75 cm2, 
respectively). 
 
3.2.3.3 Determination of cell number 
 
For determination of cell number 10 µl of the cell suspension was mixed with 90 µl 
trypan blue solutions. After 3 minutes of staining, only dead cells turn blue, while 
living cells remain unstained. The latter were counted in a Neubauer chamber. The 
numbers of cells were calculated according to the equation below. 
 
 
 
3.2.3.4 Cell extraction 
 
Cell lysates of HDMECs and RT4 cells were prepared by chemical lysis. The cells in 
culture were washed two times with cold-PBS and after third adding of cold-PBS the 
cells were scraped using a scraper on ice. Cell suspensions were collected into a 
falcon tube and centrifuged at 1200 rpm for 6 min. Supernatant was removed and 
cell pellets were washed three times more with ice-cold PBS. RT4 cell pellets were 
lysed in RIPA-Lysis buffer (3.1.3). HDMECs pellets were lysed in Triton X-100-SDS 
Lysis buffer (3.1.3). After adding lysis buffer onto the cell pellets, cell suspensions 
were mixed first by pipetting followed vortexing. Cell lysates were incubated on ice 
for 30 min and after a short vortex, incubated at RT for 10 min. After that, the cell 
lysates were centrifuged at 15,000 rpm for 15 min at 4ºC. Supernatant were collected 
and stored at -80ºC until further analyses. Protein concentration was determined 
using BCA protein assay kit (Pierce). 
 
Number of cells/ml = number of cells over a large square x dilution factor x 104 
Material and Methods 51
3.2.3.5 Transfection of HDMECs via Nucleofector 
 
HDMECs transfection was performed using the Nucleofector™ technology (Amaxa 
Biosystems). Nucleofector™ technology offers a non-viral alternative to primary cell 
transfection, which bases on a unique combination of electrical parameters and cell-
type specific solutions. HDMECs were transfected using HMVEC-L Amaxa 
Nucleofection Kit along with program S-05 on the Nucleofector device according to 
the optimized protocol of manufacturer (Amaxa). After reaching 70% confluency, the 
cells were passaged 3-4 days before nucleofection. The cells after passage ten were 
not used for nucleofection because it may lead to lower gene transfer efficiencies and 
trypsin treatment is more difficult and may damage the cells. For transfection, 
cultivated cells were harvested by trypsinization and count to determine cell density. 
5x105-1x106 cells per nucleofection were centrifuged at 1200 rpm for 10 min and 
resuspended in 100 µl Nucleofector solution and mixed with 2 µg DNA or siRNA. Cell 
suspension was transferred into an Amaxa certified cuvette and inserted into the 
cuvette holder. After running the adequate program in the Nucleofector, 500 µl of full 
medium was added to the cells and the sample could be transferred into a prepared 
culture flask. 
 
3.2.3.6 Overexpression/ gene silencing of ORM in HDMECs 
 
To overexpress ORM in HDMECs the cells were transfected with the expression 
vector pcDNA3.1(-) ORM, in which the 770 bp full-length cDNA of ORM was cloned 
into the Xhol and HindIII restriction sites of the expression vector pcDNA3.1/Hygro(-) 
(Clontech). Empty vector pcDNA3.1(-) was used as a negative control. 
ORM gene was silenced using constructed siRNA-ORM (3.2.2.15). The siRNA-
luciferase was used as negative control. 2 µg of plasmid DNA or siRNA were 
transfected into the HDMECs using nucleofector technology (3.2.3.5). Transfected 
HDMECs were cultured for 1-2 days and used for further studies. After 2 days 
supernatant of transfected cells were collected and stored at -20°C and for later 
western blot analyses.  Supernatants which were later used for tube formation assay 
(3.2.4) were centrifuged at 1200 rpm for 6 min to remove dead cells. Supernatant 
was taken and sterilised using 0.2 μm filter. To see if overexpression and gene 
silencing are effective at the protein level WB analyses were performed for 
supernatant and extract of transfected cells. Two days after transfection, cells were 
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lysed (3.2.3.4) and used for western blot analyses (3.2.1.14). After protein 
concentration measurement, same amount of total protein were loaded onto SDS-
PAGE to compare ORM level for each sample. The same blot was then striped by 
striping buffer (3.1.3) and incubated with anti vimentin antibody as control for same 
amount of loaded protein. 
3.2.4 Endothelial tube formation assay 
This assay was carried out using three-dimensional type I collagen gel (PureCol, 
Inamed) which was prepared in 48-well cluster tissue culture dishes as described 
previously (Ergun et al., 2000; Oliveira-Ferrer et al., 2004; Pepper et al., 1990). 
48-well plates were coated with 190 µl of ice-cold collagen gel mixture (3.1.3) and 
incubated over night at 37°C. After polymerization of the gel, wild type ORM-
overexpressing and ORM-silenced endothelial cells (HDMECs) were seeded onto 
solidified gels at a concentration of 4x104 cells /well in 300 µl of growth medium 
containing 5% FCS. At confluence, the medium was replaced by basal medium 
containing 2-4% FCS without further supplements. After 24 hours VEGF-A was 
added to the wells and was renewed every 3 days after taking photographs with 
phase contrast microscopy (Zeiss, Jena). The collagen gels containing endothelial 
tubes of interest were fixed overnight with Bouin´s fixative solution following overnight 
incubation with 70% ethanol and two times ethanol incubation for 1 h. The gels were 
left out from 48-well using a scalpel and embedded in paraffin to use for 
immunohistochemical studies. 
 
Stimulating Factors Description Working concentration Supplier 
ORM  Orosomucoid , human serum 1. 100 ng/ml 2. 300 ng/ml Calbiochem 
AntiPAI-1  Anti-human PAI-1 monoclonal antibody (from mouse) 15 µg/ml 
Oxford 
Biomedical 
Research 
VEGF-A Recombinant Human VEGF-A 50 ng/ml Immunotools 
  
Table 17: The stimulating factors used for tube assays  
 
To find out if PAI-1 or/and the ORM-PAI-1 complex has any function modulating 
effects on VEGF-A induced endothelial tubes, endothelial cells was seeded into 
collagen gel and incubated until confluent. Afterwards cells were left untreated or 
stimulated with; (i) VEGF-A (positive control), (ii) ORM, (iii) VEGF-A together with 
ORM, (iv) VEGF-A and anti-PAI-1 antibody, (v) VEGF-A, ORM and anti-PAI-1 
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antibody, (vi) anti-PAI-1 antibody alone (Tab. 17). Endothelial cells and VEGF-A 
induced endothelial tube formation was examined and photographed day by day 
using phase contrast microscope (Zeiss, Jena) equipped with a digital camera 
(ProgResTMC10plus, Jenoptik). 
 
3.2.5 Histological methods 
 
3.2.5.1 Fixation and HE staining for tissue samples and cells 
 
Paraffin-embedded bladder tissue sections obtained from patients who have clinically 
been diagnosed to have bladder cancer as well as normal bladder tissue, obtained 
by biopsy, sections were used for immunohistochemical analyses. The bladder tissue 
sections used in this study were obtained from department of Pathology of University 
Hospital Hamburg-Eppendorf. Before immunohistochemical staning the sections 
were stained with Hematoxylin-Eosin to confirm presence of cells on tissue sections. 
Slides containing paraffin sections were deparaffinised by incubation in order as 
three times xylene, isopropanol, 96% and 70% ethanol, and lately deionized water for 
5 min. After that, the sections were stained with Hematoxylin after a short washing 
with water, destained with acid ethanol and washed again with water. For 
cytoplasmatic staining the sections were treated with Eosin and dehydrated by 96% 
ethanol and subsequently isopropanol incubation. 
 
3.2.5.2 Immunohistochemistry 
 
Each section was deparaffinised (rehydrated) in descending alcohol row and 
incubated in 1xPBS. Then the sections were subjected to immunohistochemistry. 
After treatment with normal rabbit or normal swine serum to block the unspecific 
background for 30 min at RT, the sections were incubated with the corresponding 
primary antibodies against ORM and/or ZAG diluted in PBS-BSA-NaN3 buffer (3.1.3) 
for 24 h at 4°C. The sections were washed with 1xPBS for 3x10 min and exposed to 
the secondary antibodies for 1 h at RT. Then washed again and treated with the 
peroxidase-anti-peroxidase (PAP) for 30 min at RT. Subsequently, the sections were 
treated with ABC-complex (Vector) for 30 min at RT, washed again for 2x10 min with 
1xPBS and transferred to the solution for the immunostaining development. For the 
control reaction, same samples were incubated only with secondary antibody. 
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Peroxidase activity was enhanced and developed by means of the modified nickel-
glucose oxidase technique (Ergun et al., 1997). Glucoseoxidase solution was 
prepared freshly in dark according to the receipt described in section 3.1.3. After 
washing with 1xPB buffer (3.1.3) for 10 min, the sections were incubated with 
glucoseoxidase solution for 10-30 min at RT. Developing was followed by 
microscope. After the staining became clear, the reaction was stopped by removing 
the developing solution followed washing 3x5 min with PBS. 
Sections were counterstained with Calcium Red for 20 sec at RT and washed 2x5 
min with distilled water. The sections were dehydrated by incubation in order as 
deionized water, 70%, 96%, 100% ethanol and three times xylene for 5 min. After 
that, were embedded using histomount (Thermoshandon). In some cases Mowiol 
(Calbiochem) was used directly after Calcium red staining to embed the sections. 
Using the microscope system equipped with a digital camera the immunostaining 
were studied and photographed. 
 
3.2.5.3 Immunocytochemistry 
 
Wild type cells were seeded and cultured in chamber slides. After fixation with 4% 
paraformaldehyde for 15 min and washing 3 times with 1xPBS, the cells were 
incubated in normal serum to block the unspecific background. The cells were 
incubated with primary antibody for 24 h. After washing in 1xPBS the cells were 
incubated with biotinylated secondary antibody. Afterwards, they were washed in 
PBS and incubated with peroxidase (PAP). After washing the slides were incubated 
in avidin-biotin complex (ABC Kit, Vector). The immunostaining were developed 
using Nickel enhanced-glucoseoxidase technique (Davidoff et al., 1990) as described 
in immunohistochemistry section. If counterstaining is needed the sections were 
stained in Calcium Red for 1-2 min. Using a microscope system equipped with a 
digital camera the immunostaining were studied and photographed. Using the same 
method we have studied the localization of ORM and known angiogenic factors and 
their receptors on endothelial tubes induced in vitro after ORM overexpression 
versus ORM silencing in HDMECs. Endothelial tubes on collagen gel were fixed 
using Bouin´s fixative over night and embedded in paraffin. On 5-7 µm thick tissue 
sections immunhistochemistry were performed as mentioned above. 
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4 Results 
 
4.1 Profiling of urinary proteins by 2D gel electrophoresis 
4.1.1 Optimization of the sample preparation method for 2D gel 
 electrophoresis on human urine 
In order to determine the changes in urinary protein patterns by presence of bladder 
cancer, 2-DE analyses were performed on urine samples of fourtyfive patients with 
bladder cancer of different stages (pTa (n=12), pT1 (n=8), pT2-3 (n=8), GI, GII, GIII), 
patients on follow-up (n=10) and healthy volunteers (n=7). The details of 2-DE 
analyses were described in the section of material and methods. Protein spots were 
visualized using Coomassie Brillant Blue or silver staining. Obtained 2-DE images 
were analysed by PDQuest software programme (BioRad). Several protein spots in 
coomassie stained 2-DE gel of a patient with bladder cancer were identified using 
mass spectrometric analyses, which were not present in normal urine samples. 
It is well known that urine contains trace amounts of protein originating from blood 
plasma, the kidneys and the urogenital tract, and amounts of body filtrates such as 
water, salts, electrolytes and nitrogenous waste products (Anderson and Anderson, 
2002; Beetham and Cattell, 1993). Thus, the sample preparation of urine samples is 
very important for protein analysis and preliminary screening of biomarkers. 
In order to optimize 2-DE for urine samples several techniques including protein 
precipitation with TCA or in some cases immunoprecipitation, ultracentrifugation and 
filtration were used for sample preparation. TCA precipitation led to the vertical 
streaks on 2-DE gel probably due to residual TCA in protein sample and difficulties in 
resolubilization of proteins (data was not shown). Immunoprecipitation was used for 
detection of a specific protein and to determine changes in those proteins which 
suppose to be related to bladder cancer. However, immunoprecipitated proteins 
caused horizontal streaks and dark background on 2-DE gels probably due to the 
presence of remained immunoglobulin G leading to over loading of protein amount. 
Ultrafiltration was performed on native urine samples using Centrifugal Filter Column 
(Amicon) to remove high abundance of interfering molecules containing salts, 
electrolytes and/or some nitrogenous waste products, which disturb the 
electrophoresis process especially in the first dimension of 2-DE. After that, different 
rehydration buffers were used to solubilise filtrated and concentrated urine proteins. 
The efficiency of each buffer was compared to each other. Ultrafiltration, precipitation 
methods and different rehydration buffers were applied on urine samples and 
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compared each other to find the best method for sample preparation of urine 
samples.  The use of optimized sample preparation methods (see 3.2.1.3) revealed 
clear detectable protein spots and reduced background and streaks. 
The 2-DE protein pattern of urine sample of a patient with superficial bladder cancer 
is exemplary shown in figure 19. IPG strip with 17 cm length and 3-10 pH range was 
used for this urine sample and the protein spots were visualized using silver staining 
protocol. Many spots representing different proteins and focused particularly in the 
pH-spectrum ranging from pH 5 to 8 were seen in the silver stained 2-DE gel. 
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Figure 19: Protein pattern in urine sample of a patient with bladder cancer of the stage pTa. 
Urine sample containing 200 µg total proteins were analysed by 2-DE using 17 cm strip with pH range 
3-10. Silver staining revealed numerous spots, particularly focused in the pH range 5-8. 
4.1.2 Determination of urinary protein pattern in relation to bladder cancer by 
2-DE 
Urine samples were subdivided into three groups: urine samples of (i) healthy 
persons, (ii) patients with bladder cancer of different stages, and (iii) follow-up 
patients. 
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Firstly, it was aimed to find out possible changes in whole protein pattern of urine 
samples, which thought to be related to bladder cancer. To this aim the urinary 
protein patterns of healthy volunteers to that of patients with bladder cancer of 
different stages such as pTa, pT1, pT2 and pT3, as well as of patients on follow-up 
were compared to eachother. Several spots, which were present in urine samples of 
patients with bladder cancer and in those of follow-up, were not present in urine 
samples of healthy persons (Fig. 20-25). These protein groups were indicated with 
circles and arrows. 
4.1.3 Protein pattern of normal urine versus urine of patients with pTa 
Native urine samples obtained from healthy persons (n=7) and patients with bladder 
cancer of stage pTa (n=12) were analysed by 2-DE technique. Urine samples 
containing 200 µg total protein were loaded on IPG strips with 11 cm length and 3-10 
(NL) pH range for the first dimension of 2-DE protocol. Protein spots were visualized 
using silver staining (3.2.1.9). 
Comparison of urinary protein pattern of healthy volunteers (Fig. 20A) and patients 
with bladder cancer of stage pTa, GI (Fig. 20B) revealed big differences in pattern 
and intensity of protein spots. 2-DE images of urinary protein of different healthy 
volunteers revealed almost the same protein pattern as shown in figure 20A, 21A, 
22A. The strongest spots were seen at the sizes of 55 and 66 kDa. Using the same 
protocols and conditions, 2-DE analyses on a urine sample of pTa patients resulted 
in protein patterns showing many additional protein spots (Fig. 20B). Compared to 
healthy urine, the number and the density of detectable protein spots were higher in 
urine samples of pTa patients. The proteins which were seen as faint spots in normal 
urine were also present in urine sample of patients but in significantly higher amount. 
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Figure 20: Comparison of protein pattern in normal urine (A) and in urine of patients with 
bladder cancer of the stage pTa,GI (B). Urine samples containing 200 µg protein were loaded on 11 
cm IPG strips with pH range 3-10 non linear (NL). Protein spots were visualized by silver staining. 2-
DE image of urine sample of a healthy volunteers (A) and urine of a patient with bladder cancer of the 
stage pTa, GI (B) are shown. The protein spots at 55 and 66 kDa indicated by circles are similar in 
both urine samples, but significantly stronger in urine samples of bladder cancer (B). In urine samples 
of bladder cancer patients there are numerous additional spots as numbered (1-6). 
4.1.4 Protein pattern of normal urine versus urine of patients with pT1 
Using IPG strips with 11 cm length and 3-10 NL pH range, native urine, containing 
200 μg total protein,  of patients with bladder cancer of pT1 stages (n=8) were 
analysed by 2-DE. The 2-DE gels were stained using silver staining protocol. Protein 
pattern of the urine sample obtained from a healthy person revealed two different 
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protein spots at 55 and 66 kDa (Fig. 21A) similar to healthy urine which was shown in 
figure 20A. The urinary protein pattern of a patient with bladder cancer of stage 
pT1,GIII revealed several additional protein spots, compared to normal urine (Fig. 
21B).  
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Figure 21: Comparison of protein pattern in normal urine (A) and in urine of patients with 
bladder cancer of the stage pT1, GIII (B). Urine samples containing 200 µg total proteins were 
loaded on 11 cm IPG strips with pH range 3-10 NL. Protein spots were visualized by silver staining. 
The protein spots indicated by cycles in healthy urine (A) and in urine of patient with bladder cancer of 
the stage pT1, GIII (B) are similar. There are additional spots which were numbered and indicated by 
doted sequares (1-7) in urine samples of patients. Among marked protein spots, especially the protein 
groups at 55 kDa are stronger in urine samples of patients (B). 
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The spots at 55 and 66 kDa, which were also present in normal urine, were seen in 
urine of pT1 patients too. But the protein group at 55 kDa was present in urine of pT1 
patients in a significant higher amount than that in normal urine. Spot 1 and spot 2, 
detected in urine of pTa patients, were not present in urine of pT1 patients and also 
were not present in normal urine. Spot 3-6 were detected in urine samples of both 
patients, either pTa and pT1 bladder cancer but they were much stronger present in 
urine of pTa patients shown in figure 20B.  In urinary pattern of pT1 patients, 
additional protein spots numbered as 7 were detected. Spot 7 representing several 
different proteins, at 35-45 kDa, was not present in the urine of samples pTa patients. 
4.1.5 Protein pattern of normal urine versus urine of patients with pT2 
Urine samples containing 200 µg total protein were obtained from patients with 
bladder cancer of invasive stages as pT2-3 (n=8) and were separated using 2-DE 
technique. For the first dimension IPG strips with 11 cm length and 3-10 NL pH range 
were used. The protein spots on 2-DE gels were visualized using silver staining 
protocol (3.2.1.9). Protein pattern of healthy urine (Fig. 22A) revealed the similar 
protein spots at 55 and 66 kDa as shown for urine samples of healthy volunteers in 
figure 20A and 21A. The 2-DE image obtained from analyses of urine sample of a 
patient of bladder cancer with stage pT2, GIII revealed protein spots at 55 and 66 
kDa (Fig. 22B) which were also present in normal urine, as well as in urine of pTa 
and pT1 patients, but in comparison to the stages pTa and PT1, these protein spots 
were weaker in the urine samples of pT2 patients. The protein spot at 55 kDa was 
stronger in urine samples of patients with pT2 than the normal urine. Spot 1, which 
was not present in the urine samples of pT1 patients, was present in the urine 
samples of pT2 patients as well as in pTa patients. Spot 2 was not present in urinary 
protein pattern of pT2 patients, in similarity with that of pT1 patients. Spot 3 and 5, 
which were present in the urine samples of pTa and pT1 patients, were also detected 
in the urine samples of pT2 patients. Spot 4 and 6 were not detectable in urine of pT2 
patients in contrast to the detection of these spots in urine samples of pTa and pT1 
patients. Spot 7, which was seen only in the urine samples of pT1 patients (Fig. 21B), 
was not present in the urine samples of pT2 patient. Additional spots numbered as 8, 
9 and 10 were present only in the urine samples of pT2 patients. 
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Figure 22: Comparison of protein pattern in normal urine (A) and in urine of patients with 
bladder cancer of the stage pT2, GIII (B). 200 µg urinary proteins were loaded on 11 cm IPG strips 
with pH range 3-10 NL. Protein spots were visualized by silver staining. The protein spots at 55 and 66 
kDa indicated by circles are similar in both urine samples, healthy urine (A) and urine of a patients with 
bladder cancer of the stage pT2,GIII (B). In urine samples of patients with bladder cancer of the stage 
pT2,GIII additional protein spots and numbered as 1, 3, 5, 8, 9,10 were detected.  
4.1.6 Protein pattern of urine samples of follow-up versus urine samples of 
 bladder cancer pateints  
In the next step, protein pattern of the urine samples of patients on follow-up (n=10) 
and patients with bladder cancer of different stage (pTa, pT1, pT2-3) were compared. 
For 2-DE analyses of urine samples obtained from patients on follow-up, IPG strips 
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with 11 cm length and 3-10 NL pH range were used. Native urine containing 200 µg 
total proteins were loaded and the gels were visualized using silver staining protocol.  
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Figure 23: Comparison of protein pattern in urine of patients on follow-up (A) and patients with 
bladder cancer of the stage pTa, GI (B). 200 µg proteins, involved in urine samples, were loaded on 
11 cm IPG strips with pH range 3-10 NL. Protein spots were visualized by silver staining. The protein 
spots, at 55 and 66 kDa, which are marked with circles, are seen in urine samples of patients on 
follow-up (A) and patients with bladder cancer of the stage pTa, GI (B). Additionally, the protein spot 
numbered as 3, which was detected in urine sample of patients with bladder cancer (shown in figure 
21B, 22B, 23B) is also present in urine sample of patients on follow-up. 
2-DE spots groups at 55 and 66 kDa marked with doted circles were detected in 
urine of follow-up patients with similarity to all urine samples used including urine 
samples of healthy persons and patients with bladder cancer. However, the density 
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of these proteins was stronger in urine samples of patients with bladder cancer of 
different stages and patients on follow-up than those in urine of healthy persons. 
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Figure 24: Comparison of protein pattern in urine of patients on follow-up (A) and patients with 
bladder cancer of the stage pT1, GIII (B).  Urine samples containing 200 µg proteins were used for 
2-DE analyses. 11 cm IPG strips with pH range 3-10 NL were used. For detection of proteins, silver 
staining was used. The spots groups, at 55 and 66 kDa, indicated by circles are similar in urinary 
protein pattern of patients on follow-up (A) and patients with bladder cancer of the stage pT1,GIII (B). 
The protein spots numbered as 4, which was seen in urine sample of pTa and pT1 patients (Fig. 21B, 
22B), is also present in urine samples of patients on follow-up. 
In comparison of urinary pattern of patients on follow-up (Fig. 23A, 24A, 25A) and 
patients with bladder cancer of different stage such as pTa,GI (Fig. 23B), pT1,GIII 
(Fig. 24B), pT2,GIII (Fig. 25B) revealed similar but also different spots in urinary 
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protein patterns. In 2-DE gels of urine samples of patients on follow-up, there are few 
detectable and faint stained protein spots in addition to protein spot groups marked 
by doted circles. 
4.1.7 Protein pattern of urine samples of patients on follow-up versus that of 
 patients of tumor stage pTa 
As mentioned above the protein spots at 55 and 66 kDa were present in urine 
sample of follow-up patients as marked by doted circles (Fig. 23A). The densities of 
these protein groups seen in urine samples of patients on follow-up were as strong 
as in that of patients having bladder cancer. The additional protein spot numbered as 
3 was detected in urine samples of patients on follow-up, which was not present in 
normal urine but prominently present in urine samples of patients with bladder cancer 
of stage pTa (Fig. 23B). Many additional spots representing different proteins, as 
shown and numbered for the same image in figure 20B, were detected in urine 
samples of patients with pTa, in comparison to urine samples of patients on follow-
up. 
4.1.8 Protein pattern of urine samples of patients on follow-up versus that of 
 patients of tumor stage pT1 
The protein spots at 55 and 66 kDa were present also in urine samples of another 
patient on follow-up as shown in figure 24A. These spots were marked as doted 
circles. The protein spot at about 30 kDa marked as number 4 was detected in urine 
sample of pateints on follow-up and also patients with bladder cancer of pT1 (Fig. 
24A,B). The same protein spot was also present in urine sample of pTa patients and 
was indicated with the same number in figure 20B. The density of spot 4 was higher 
in urine sample of the patients with bladder cancer stage pT1 (Fig. 24B) then the 
follow-up patients. But the additional protein spots, which were numbered for the 
same image in figure 21B, were seen only in the urine samples of patients with 
bladder cancer. 
4.1.9 Protein pattern of urine samples of patients on follow-up versus that of 
 patients of bladder cancer stage pT2 
The protein spot at 66 kDa as marked by doted circle was not present in urine 
sample of this follow-up patient as shown in figure 25A. But the spot at 55 kDa was 
present in urine sample of a patient on follow-up (Fig. 25A) in a higher intensity as in 
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the urine sample of a pT2 patient (Fig. 25B). The protein spots numbered as 3, 4, 
and 5 were present in urine samples of both patients on follow-up and those with 
bladder cancer stage pT2/GIII.  
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Figure 25: Comparison of protein pattern in urine of patients on follow-up (A) and patients with 
bladder cancer of the stage pT2, GIII (B).  Urine samples containing 200 µg protein were loaded on 
11 cm strips with pH range 3-10 NL. Silver staining was used for detection of protein spots. The 
protein spots seen at 55 kDa which marked by circles are similar in both sample, urine of follow-up 
patients (A) and and patients with bladder cancer of the stage pT2, GIII (B). The protein spot at 66 
kDa, which was seen in other 2-DE images is not visible in urine sample of this follow-up patient (A). 
The protein spot marked by a fat square in figure A is not present in urine samples of pT2 patients (B). 
Another protein spot in figure B marked by fat square is not present in urine samples of follow-up 
patients. The protein spots numbered as 3, 4, and 5 are present in both urine samples.  
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The spot marked as fat square in 2-DE of urine sample of a patient on follow-up (Fig. 
25A) was not present in urine sample of patient with bladder cancer stage pT2 (Fig. 
25B). On the other hand, another protein spot ,marked by fat square, present in urine 
sample of a patient with tumor stage pT2 (Fig. 25B) was not seen in urine sample of 
a patient on follow-up (Fig. 25A).  In summary, two different groups of spots at 55 
and 66 kDa were present in all urine samples (Fig. 20-25), but they were particularly 
prominent in urine samples of patients with bladder cancer and patients on follow-up. 
Numerous additional proteins were detected in urine samples of patients with bladder 
cancer in comparison to other groups of urine samples, including healthy persons 
and follow-up patients, which were analysed in this study. 
4.1.10 Identification of protein spots in urine samples of patients with bladder 
 cancer 
Proteins from urine samples of patients with bladder cancer stage PTa/GI were 
separated on a 2-DE gel and stained with both silver and CBB (Fig. 26). 
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Figure 26: Protein identification from 2-DE image of urine of a patient with bladder cancer of 
the stage pTa/GI. The urinary pattern of a patient with bladder cancer of the stage pTa/GI was 
chosen for protein identification.  Nine protein spots indicated by quadrates in Coomassie stained 2-
DE gel were cut out and subsequently underwent mass spectrometric analyses. 
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Several protein spots observed in urine samples of patients with bladder cancer of 
the stage PTa/GI were cut out from the coomassie stained gel and underwent mass 
spectrometric analyses. After these studies, several proteins called as uromodulin, 
DNA-binding glycoprotein, human serum albumin (HSA), orosomucoid1 (ORM), 
human zinc-alpha-2-glycoprotein and complex-forming glycoprotein (HC) have been 
identified (Tab. 18). 
Spot 
Number Match to Score 
NCBI database 
reference 
Sequence 
Coverage (%) 
1 Uromodulin; Tamm-Horsfall glcoprotein; uromucoid (Homo sapiens) 38 gi | 4507833 11 
2 Nuclear DNA-binding protein (Homo sapiens) 36  gi | 37550855 - 
3 Ribosomal Protein S19 (Homo sapiens) 39 gi | 3164200 - 
4 Human Serum Albumin (Homo sapiens) 164 gi | 4389275 63 
5 Human Serum Albumin (Homo sapiens) 229 gi | 4389275 74 
6,7 Orosomucoid 1 precursor (Homo sapiens) 152  gi | 20070760 38 
8 Human Zinc-Alpha-2-Glycoprotein (Homo sapiens) 212 gi | 4699583 72 
9  Complex-forming glycoprotein HC (Homo sapiens) 94     gi | 223373 41 
 
Table 18: Proteins idendified by MS analyses. For spot 2 and 3 no sequence coverage was 
determined. These protein spots were predicted to be Nuclear DNA-binding protein (spot2) and 
Ribosomal protein S19 (spot3). 
One of these proteins, tamm-horsfall glycoprotein (Fig. 26, spot 1), also referred to as 
uromodulin, is one of abundant protein in normal urine. In 2-D images the spot 
belonging to uromodulin (mentioned as the spot at 66 kDa in figure 20-25) was 
prominently present in the urine sample of patients with bladder cancer but almost 
equally present in the urine of healthy volunteers and patients on follow-up. DNA-
binding protein (Fig. 26, spot 2) included in spot group at 66 kDa as shown in figure 
20-25 was particularly prominent in urine samples of patients with bladder cancer but 
almost equally present in urine samples of patients on follow-up and healthy 
volunteers. The spots 4 and 5 (Fig. 26) were identified as human serum albumin, 
which were present in all urine samples analysed in this study. These spots were in 
similarity with spots marked by doted circles for the protein at 55 kDa as shown in 
figures 20-25. The spots representing human serum albumin were particularly 
prominent in urine samples of patients with bladder cancer and patients on follow-up. 
The proteins indicated as spot 6 and 7 in figure 26 were identified as orosomucoid 1 
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and they were present only in urine samples of patients with bladder cancer (shown 
in figure 20B as spot 2), but were absent in urine samples of healthy persons and 
patients on follow- up. The spot marked with the number 8 in figure 26 was identified 
as human zinc-alpha-glycoprotein and was prominently present in the urine samples 
of patients with bladder cancer (Fig. 20-25, included in spot 3) and in those of 
patients on follow-up. But it was absent in urine samples of healthy persons. The 
spot 9 in figure 26 was identified as complex-forming glycoprotein (alpha-1-
microglobulin, also called HC). This protein was found in urine samples of patients 
with bladder cancer, particularly strong in the stage of pTa, and visible as a faint spot 
(Fig. 20-25, included in spot 4) in urine samples of patients on follow-up (Fig. 23-25). 
In contrast, it was not detectable in urine samples of healthy persons. The spot 3 in 
figure 26, which was identified as ribosomal protein S19, was not present in normal 
urine, but no considerable changes were seen for this protein in urine samples of 
patients with bladder cancer and patients on follow-up. It is included in the spot group 
marked by doted circle at 55 kDa (Fig. 20-25). The changes in density of identified 
proteins in urine samples were summarized in table 19. 
Spot 
number Idendified Proteins Healthy Follow-up pTa pT1 pT2-3 
1 Uromodulin -/+ -/+    
2 DNA-binding protein -/+ -/+    
3 Ribosomal Protein S19 -/+     
4,5 Human Serum Albumin -/+     
6,7 Orosomucoid 1 --- ---    
8 Human Zinc-Alpha-2-Glycoprotein --- --- 
   
9 Complex-froming gylcoprotein --- -/+ 
  -/+ 
 
Table 19: Semiquantitative determination of protein levels of identified proteins in urine 
samples by 2-DE. 
4.1.11 Human serum albumin in normal urine versus in urine samples of 
 patients with bladder cancer and follow-up 
The 2-DE results showed that most abundant proteins in urine samples, which were 
analysed in this study, were detected at 55 and 66 kDa. One of these protein spots, 
at 55 kDa, was identified as human serum albumin using mass spectrometry (Tab. 
18).  To view changes in the amount of human serum albumin in normal urine 
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samples and urine samples of patients with bladder cancer the urinary protein 
patterns of all groups of urine samples were compared to each other.  
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Figure 27: Comparison of protein spots indicating human serum albumin (HSA) in all urine 
sample groups.  The protein spots at 55 kDa, which are present in all urine samples, were identified 
as Human Serum Albumin. The protein pattern of healthy urine (A), urine of patients on follow-up (B), 
and patients with bladder cancer with different stages (urinary pattern of a patient with pTa, GI was 
shown as exemplary) (C) were compared to each other for the spots showing HSA. The protein spots 
of HSA are stronger in urine samples of patients with bladder cancer and patients on follow-up in 
comparison to healthy persons. 
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Human serum albumin was present in all urinary protein patterns (Fig. 27 A-C), but 
the strongest protein spots which belong to human serum albumin were detected in 
urine of patients with bladder cancer (Fig. 27C) and patients on follow-up (Fig. 27B) 
when compared to those in healthy urine (Fig. 27A). 
4.1.12 Mass spectrums and matched peptides for identified proteins 
Proteins were identified by searching the NCBI database as shown for all identified 
proteins in urine samples of patients with bladder cancer (Fig. 26). Spectrum of mass 
spectrometric analyses and matched sequences were given for spot 1 which was 
identified as uromodulin (Fig. 28); spot 2 and 3 which were identified as similar to 
DNA-binding glycoprotein and ribosomal protein (Fig. 29A-B); spot 4 and 5 which 
were identified as human serum albumin (Fig. 30A,B); spot 6 and 7 which were 
identified as orosomucoid1 (Fig. 31); spot 8 which was identified as zinc-alpha-2-
glycoprotein, and spot 9 identified as Complex-forming glycoprotein (Fig. 32A,B).  
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Figure 28: MS identification of Uromodulin (spot 1). Matched peptides are in red.  
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Figure 29: MS identification of DNA binding glycoprotein and ribosomal protein.  Spot 2 was 
idendified as DNA binding glycoprotein (A) and spot 3 was identified as Ribosomal protein (B).  
Matched peptides were not given for this two proteins. 
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Figure 30: MS identification of Human Serum Albumin (HSA). Spot 4 (A) and spot 5 (B) were 
identified as human serum albumin. Matched peptides are in red.  
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Figure 31: MS identification of orosomucoid 1. Spot 6 (A) and spot 7 (B) were identified as 
orosomucoid. Matched peptides are in red.  
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Figure 32: MS identification of Zinc-alpha-2-glycoprotein (ZAG) and Complex forming 
glycoprotein. (spot 8, 9). Spot 8 (A) was identified as Human zinc-alpha-2-glycoprotein and spot 8 
(B), as Complex forming glycoprotein (HC). Matched peptides are in red.  
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4.2 Idendification of two urinary proteins using Western blot analyses 
4.2.1 Detection of orosomucoid (ORM) in urine samples of healthy persons, 
 patients with bladder cancer and patients on follow-up 
In urine samples (n=45) of all bladder tumor stages classified as pTa, pT1, pT2, pT3 
ORM was detected at the size of 41 kDa by Western blot analyses using the 
polyclonal anti-ORM antibody (Fig. 33A). ORM was also found in the urine samples 
of patients on follow-up and healthy volunteers, but prominently in the urine samples 
of patients with bladder cancer, particularly in the invasive tumor stages as pT2-3. 
Compared to healthy volunteers ORM was increased by three times in 85 % of urine 
samples of bladder cancer patients on follow-up, by seven times in 83 % of patients 
with pTa, 16 times in 85 % of patients with pT1, and twenty times in 71 % of patients 
with pT2-3. 
pT3pT2pT1pTaFollow-upHealthy
45 kDa
B
pT3pT2pT1pTaFollow-upHealthy
41 kDa
A
 
Figure 33: Detection of ORM and ZAG in urine samples. Western blot analyses using polyclonal 
anti-ORM antibody revealed ORM (A) at the referred size of 41 kDa in urine samples of patients of 
follow-up and in highest amount in urine samples of patients with invasive bladder cancer stages pT2-
3. In similar pattern of ORM, western blot analyses using a polyclonal anti-ZAG antibody revealed 
ZAG at the expected size of 45 kDa in urine samples (B) of patients on follow-up and patients with 
bladder cancer.  
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4.2.2 Detection of zinc-alpha-2-glycoprotein (ZAG) in urine samples of 
 healthy persons, patients with bladder cancer and patients on follow-up 
Zinc-alpha2-glycoprotein (ZAG) was detected at the size of 45 kDa in urine samples 
(n=45) of all bladder tumor stages classified as pTa, pT1, pT2, pT3  by western blot 
analyses using the monoclonal anti-ZAG antibody (Fig. 33B). ZAG was also found in 
urine samples of patients on follow-up and healthy volunteers but prominently in 
urine sample of patients with bladder cancer, particularly in invasive tumor stages 
such as pT2-3. Compared to urine samples of healthy volunteers, ZAG was 
increased by four times in 85 % of urine sample of bladder cancer patients on follow-
up, by sixteen times in 75 % of those patients with pTa, by five times in 85 % of those 
of patients with pT1, and twenty times in 71 % of those of patients with pT2-3. 
4.3 Expression pattern of ORM and ZAG in bladder cancer versus normal 
 bladder tissue 
 
To localize ORM and ZAG proteins in human urinary bladder tissue comparing tumor 
and normal tissue areas immunohistochemical analyses were performed on paraffin 
sections of bladder tissue. 
Immunohistochemistry for ORM revealed no considerable staining in normal areas of 
bladder tissue (Fig. 34A) whereas endothelial cells of large and small blood vessels 
within tumor tissue (Fig. 34B) or in close proximity of tumor tissue (Fig. 35A) 
exhibited ORM. In addition to the blood vessels, also some single cells, probably 
inflammatory cells (Fig. 35B), within or around the tumor tissue were strongly positive 
for ORM. Also a part of tumor cells exhibited ORM, particularly those of invasive 
tumor stages as pT2 and pT3 (Fig. 35A). ZAG immunostaining was found at the 
luminal surface of normal urothelium (Fig. 36A) which disappeared in superficial 
bladder tumors as pTa (Fig. 36A). Concurrently, one or two cell rows at the basal 
side of pTa expressed ZAG (Fig. 36A). Interestingly, the ZAG immunostaining was 
most prominent in tumor cells located at the invasive front (Fig. 36B) where tumor 
cells invade the lamina propria of bladder wall marking the transition of tumor from 
pTa to pT1 stage. 
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Figure 34: Localization of ORM in normal and bladder tumor tissue. In normal bladder tissue 
there is no considerable staining for ORM, neither in transitional epithelium (TE) nor in blood vessels 
(A). In contrast, blood vessels (arrows) of tumor tissue are strongly positive for ORM (B).  
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Figure 35: Localization of ORM in bladder tumor cells. Vascular endothelial cells (arrows) and 
positive for ORM in close proximity of bladder tumor tissue, but also some tumor cells (arrow heads) 
exhibit ORM immunostaining (A). Inflammatory cells (arrows) within the tumor tissue also show 
positive ORM staining (B).  
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Figure 36: Localization of ZAG in bladder tumor tissue. ZAG immunostaining is localized at the 
luminal surface of normal transitional epithelium (arrows) which switches to the basal side of bladder 
epithelium (arrow heads) when superficial bladder tumor such as pTa is seen (A). The strongest 
staining of ZAG is found in tumor cells located at the invasive front (B).  
 
4.4 Localization of ORM on endothelial cells (HDMECs) by 
 immunocytochemistry 
 
To determine whether the ORM staining in vascular endothelial cells due to 
endogenous production or only due to the endothelial binding of ORM produced by 
other cells immunostaining for ORM on cultivated human primary microvascular 
endothelial cells (HDMECs) were performed. These studies confirmed the results 
from immunohistochemistry on bladder cancer tissue and revealed a strong staining 
for ORM in HDMECs (Fig. 37A) while the cells were mostly negative for ZAG (Fig. 
37B). ORM immunostaining was also present in cultivated bladder cancer cell line 
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RT4 but weaker than in HDMECs (Fig. 38A). In contrast, ZAG was not detectable in 
RT4 cells (Fig. 38B). The presence of ORM in endothelial cells was confirmed by 
western blot analyses (Fig. 39A) whereas ZAG was neither detectable in protein 
extract of RT4 nor in that of HDMECs. 
A
B
 
 
Figure 37: Immunocytochemical staining for localization of ORM and ZAG in HDMECs. 
Cultivated human dermal microvascular endothelial cells (HDMECs) are strongly positive for ORM 
(arrows, A), but are mostly negative for ZAG (B).  
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Figure 38: Immnucytochemical staining for localization of ORM and ZAG in bladder cancer cell 
line. ORM staining is also present in bladder cancer cell line RT4, but its expression is weaker than in 
HDMECs (arrows, A). ZAG is not detectable in RT4 cells (B). 
 
 
 
HDMEC RT4
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A
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Figure 39: Detection of ORM in HDMECs and RT4 cell line. Western blot analyses using anti ORM 
antibody confirm the immunohistochemical data and show ORM at the expected size of 41 kDa in 
HDMECs (A). ORM was not seen in bladder cancer cell line RT4. The control of protein loading was 
performed by immunoblotting using anti-vimentin antibody (B). 
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4.5 ORM overexpression versus ORM gene silencing in HDMECs 
 
To address the role of ORM in angiogenesis, ORM overexpression versus ORM 
gene silencing were performed in HDMECs. The effeciency was confirmed by 
western blot analyses which were performed on supernatant and protein extracts of 
transfected HDMECs (Fig. 40). ORM protein was detectable at 41 kDa in lysate of 
ORM overexpressing endothelial cells (Fig. 40A) and their supernatant (Fig. 40C) 
using polyclonal anti-ORM antibody. Empty vector transfected endothelial cells (Fig. 
40A, Lane1) produce ORM as described in previously published data in the literature 
(Sorensson et al., 1999). A significantly higher amount of ORM was detected in the 
protein extract of ORM-overexpressing HDMECs in comparison to empty vector 
transfected HDMECs (Fig. 40A, Lane2). But ORM expression was almost completely 
reduced in HDMECs transfected simultaneously with ORM expressing vector plus 
ORM-siRNA (Fig. 40A, Lane3). The specificity of ORM siRNA was confirmed using 
siRNA for luciferase, which did not cause any significant reduction of ORM in 
contrast to ORM siRNA (Fig. 40A, Lane4). On the other hand, as shown in figure 
40C, the majority of ORM after its overexpression in HDMECs was detected in 
supernatant of ORM expressing HDMECs (Fig. 40C, Lane2). ORM was detectable 
as a faint band in supernatant of empty vector transfected cells (Fig. 40C, Lane1). 
 
41 kDa
1 2 3 4
A
41 kDa
1 2 3 4
C 
55 kDa
B  
Figure 40: Overexpression and gene silencing via siRNA for ORM in human dermal endothelial 
cells (HDMECs). The ORM amount in cell extract of ORM-overexpressing HDMECs (A, Lane2) is only 
slightly higher as in the control. The use of ORM-siRNA reduces the ORM amount significantly below 
the endogenous level (A, Lane1). No change is seen by application of luciferase siRNA used as 
negative control (A, Lane4). Control of protein loading for cell lysates was performed by 
immunoblotting using anti-vimentin antibody (B). Immunoblotting using anti-ORM antibody reveals 
high amount of ORM at the size of 41 kDa in the supernatnats (C) of ORM-overexpressing HDMECs 
(C, Lane2), which is sucsessfully reduced by additional transfection with ORM-siRNA (C, Lane3) while 
luciferase siRNA used as control did not change the ORM amount (C, Lane4).  
Results 83
The transfection of HDMECs with ORM siRNA reduced ORM protein amount (Fig. 
40C, Lane3) while luciferase siRNA which used as a negative control did not change 
the ORM amount (Fig. 40C, Lane 4). 
 
4.6 Mechanistic studies via in-vitro angiogenesis assays 
4.6.1 In-vitro endothelial tube formation using ORM-overexpressing versus 
 ORM–silenced HDMECs 
To find out the potential effects of ORM in angiogenesis and capillary morhogenesis, 
in-vitro endothelial tube formation assay was performed.  
A B
C D
 
Figure 41: Endothelial tube formation assay. VEGF-induced endothelial tubes (arrows; A) are 
enhanced by combined application of VEGF-A and the supernatant of ORM-overexpressing HDMECs 
(arrows; B). The treatment with VEGF-A and supernatant of HDMECs transfected with ORM 
expressing vector plus ORM-siRNA reduced the tube formation (C) in comparison to VEGF-A alone 
(A) and VEGF-A plus supernatant of ORM overexpressing HDMECs (B). Untreated endothelial cells  
were used as a negative control (D). 
 
The supernatant of ORM-overexpressing and ORM-silenced HDMECs were used in 
endothelial tube formation assay. HDMECs were transfected with empty vector, ORM 
expressing vector, and ORM siRNA using nucleofector technology as described in 
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material and methods (3.2.3.5). VEGF-A was used as a positive control which 
induced endothelial tube formation (Fig. 41A) as expected. The number and the 
network of VEGF-A induced endothelial tubes were increased by combined 
application of VEGF-A and the supernatant of ORM-overexpressing HDMECs (Fig. 
41B). Combined application of VEGF-A, supernatant of HDMECs transfected with 
ORM expressing vector and ORM siRNA simultaneously did not affect VEGF-
induced endothelial tubes (Fig. 41C). Untreated endothelial cells were used as a 
negative control and did almost not induce tubes (Fig. 41D). 
4.6.2 The interaction between ORM and PAI-1 in endothelial tube formation 
Since it was reported that a complex composed of PAI-1 and ORM on the endothelial 
cells surface influences the behaviour of endothelial cells, it was aimed to study 
potential effect of the interaction between ORM and PAI-1 in capillary 
morphogenesis. To this aim, untreated endothelial cells were cultured and at 
passage 4 the cells were seeded onto collagen gel and cultured until confluence. 
Afterwards, endothelial cells were stimulated with: (i) ORM, (ii) VEGF-A, (iii) anti-PAI-
1 antibody alone and with different combination of these factors. Two different 
concentration of ORM as 100 and 300ng/ml were used for stimulation of HDMECs. 
Endothelial cells exposed only to basal medium were used as negative control and 
did not form tubes (Fig. 42A).VEGF-A was used as a positive control and induced 
endothelial tube formation as also mentioned in tube assay studies above (Fig. 42B). 
ORM, at 100 ng/ml concentration, alone did almost not induce tube formation as also 
observed in cases of untreated cells (Fig. 42C). Treatment with anti-PAI-1 antibody 
alone, which was used to block PAI-1 protein, induced the formation of a few 
endothelial tubes in contrast to ORM alone (Fig. 42D). To test the effects of the 
combined application of ORM and anti-PAI-1 the cells were stimulated with these 
factors alone or in combination with VEGF-A. The application of ORM at 100 (Fig. 
43A) and 300 ng/ml (Fig. 43B) plus VEGF-A simultaneously increased the VEGF-A 
induced endothelial tubes depending on the applied concentration of ORM. 
Combined application of VEGF-A and anti-PAI-1 increased the network and the 
number of VEGF-induced tubes too (Fig. 43C). Treatment of endothelial cells with 
ORM at 300 ng/ml and anti-PAI-1 induced a few tubes (Fig. 43D). The combined 
application of all three factors as ORM, anti-PAI-1, and VEGF simultaneously 
exhibited the strongest effect on endothelial tube formation. The application of anti-
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PAI-1 and ORM at 300 ng/ml (Fig. 44B,C) in combination with VEGF-A increased 
more endothelial tubes than the combination of VEGF-A and 100 ng/ml of ORM with 
anti-PAI-1 (Fig. 44A). 
 
A B
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Figure 42: Effect of ORM and anti-PAI-1 antibody on endothelial tube formation. In comparison 
to untreated HDMECs, as negative control (A), and VEGF-A treated cells, as positive control (B), ORM 
(C) did not effect endothelial tubes, while treatment of antibody against PAI-1 formed several 
endothelial tubes (D), but it is not a considerable effect. Wild type HDMECs were stimulated with 100 
ng/ml ORM protein and 15 ng/ml of anti-PAI-1 antibody. 
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Figure 43: Effect of ORM and anti-PAI-1 at VEGF-induced endothelial tubes.  By combined 
application of VEGF-A and ORM protein, at two different concentrations as 100 (A)and 300 ng/ml (B), 
the numbers of VEGF-induced endothelial tubes are significantly increased in correlation with applied 
ORM concentration. The treatment with VEGF-A plus anti-PAI-1 antibody induces a higher increase of 
VEGF-induced endothelial tubes in comparison to ORM application (arrows, C). Combined application 
of 300 ng/ml of ORM and anti-PAI-1 antibody does not effect endothelial tube formation (D). 
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Figure 44: Effect of VEGF, ORM and anti-PAI-1 combination on endothelial tube formation. 
VEGF-induced endothelial tubes are exteremly increased by combined application of ORM, as 100 
ng/ml (arrows, A) and 300 ng/ml concentration (arrows, B,C) with anti-PAI-1 antibody. Increase of 
VEGF-induced endothelial tubes correlates with ORM concentration. 
 
4.7 Immunolocalization of ORM in in-vitro induced endothelial tubes 
 
Endothelial tubes on collagen gel which were formed by wild type HDMECs after 
treatment with stimulating factors such as ORM, VEGF-A and anti-PAI-1, were fixed 
using Bouin´s fixative over night and embedded in paraffin. On paraffin sections of 5-
7 μm thickness obtained from paraffin embedded tissue block of in-vitro induced 
endothelial tubes immunhistochemistry was performed using polyclonal anti-ORM 
antibody. Untreated endothelial cells and tubes on collagen gel revealed a weak 
staining for ORM (Fig. 45A) in comparison to endothelial tubes induced by VEGF-A 
(Fig. 46A). There is no immunostaining in control sections exposed only to secondary 
antibody (Fig. 45B; Fig. 46B). Endothelial tubes induced by treatment with anti-PAI-1 
alone exhibited stronger immunostaining for ORM (Fig. 47A) in comparison to tubes 
induced by combined application of VEGF and anti-PAI-1 (Fig. 47B). 
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Figure 45: Localization of ORM on wild type endothelial cells after tube formation assay. 
Unstimulated wild type HDMECs (arrows) in collagen gel revealed a weak staining for ORM (A). In 
control section, no staining is seen (B). 
 
No staining was detected in control section of endothelial tubes induced by treatment 
with anti-PAI-1 alone (Fig. 47C). Endothelial tubes induced by application of ORM at 
100 ng/ml alone exhibited stronger ORM immunostaining (Fig. 48A) in comparison to 
endothelial cells treated only with basal medium (Fig. 45A). But the treatment of 
endothelial cells with ORM at 100 ng/ml and anti-PAI-1 revealed strongest ORM 
immunostaining on endothelial cells (Fig. 48B,C). Interestingly, in the case of 
treatment of endothelial cells with the same combination but a higher concentration 
of ORM as 300 ng/ml ORM immunostaining on endothelial tubes was almost weaker 
than the use of ORM at 100 ng/ml (Fig. 49A,B). The control section of endothelial 
tubes treated with ORM at 300 ng/ml and anti-PAI-1 which was exposed only to the 
secondary antibody did not show ORM immunostaining (Fig. 49C). Immunostaining 
for ORM was most prominent in sections obtained from endothelial tubes treated with 
ORM at 300 ng/ml, anti-PAI-1 antiobody and VEGF-A simultaneously (Fig. 49D). 
To define exact changing in number and network of endothelial tubes which were 
induced by treatment with ORM plus anti-PAI-1 plus VEGF-A, during their growing on 
collagen gel, the length of endothelial tubes were measured. After the cells have 
been stimulated with the factors mentioned above the photographs of wells 
containing endothelial collagen gel were taken every day using phase contrast 
microscope  
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Figure 46: Immunostaining for ORM on VEGF-induced endothelial tubes. There is positive 
immunostaining for ORM on endothelial cells forming VEGF-induced tubes, which were used as 
positive control (arrows, A). Control section is negative for ORM (B). 
 
(Zeiss, Jena). The endothelial tubes were marked with arrows and the length of each 
endothelial tube was measured. Total lengths of all tubes induced by a factor or a 
combination of factors were determined for each sample and the values were 
summarized in table 20. 
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Figure 47: Localization of ORM on endothelial tubes treated with anti-PAI-1 antibody. ORM is 
strongly positive in endothelial cells forming tubes by blocking of PAI-1 (arrows, A) in comparison to 
combined application of VEGF-A and anti-PAI-1 antibody (arrows, B). The control section shows no 
specific staining (C).  
 
The quantification of endothelial tubes as mentioned above revealed that the 
application of VEGF alone induces endothelial tubes in considerable amount as 
expected (Tab. 20, column2) while endothelial cells treated with basal medium as a 
negative control did not form endothelial tubes (Tab. 20, column1). 
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Figure 48: Localization of ORM on endothelial tubes treated with ORM in low concentration and 
anti-PAI-1 antibody. Endothelial cells forming tubes by ORM  stimulation (100 ng/ml) are significantly 
positive for ORM (arrows, A), while the application of the same ORM concentration with the antibody 
against PAI-1 shows stronger immunostaining for ORM (arrows, B, C). 
 
The application of anti-PAI-1 alone to endothelial cells was capable to form a few 
tubes (Tab. 20, column4) but not the individual addition of ORM, while application of 
ORM at 100 ng/ml plus VEGF enhanced the length of VEGF-induced endothelial 
tubes significantly (Tab. 20, column5). 
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Figure 49: Localization of ORM on endothelial tubes treated with ORM in high concentration 
with anti-PAI-1 antibody. Interestingly, application of ORM at 300 ng/ml with anti PAI-1 antibody 
leads to a weaker staining for ORM on endothelial tubes compared to the same combination with low 
concentration of ORM at 100 ng/ml (arrows, A,B). The control section is negative for ORM (C). The 
strongest staining for ORM in endothelial tubes is seen by treatment of endothelial cells with VEGF, 
ORM at 300 ng/ml and anti PAI-1 antibody (arrows, D). 
 
Additional increase of the length of endothelial cells tubes was achieved when VEGF 
plus ORM (100 ng/ml) plus anti-PAI-1 were applied to endothelial cells on collagen 
gel (Tab. 20, column9). The most increase of VEGF-induced endothelial tubes was 
seen by the combined application of VEGF, anti-PAI-1 and ORM in 300 ng/ml 
concentration (Tab. 20, column8). Also the combined application of ORM (300 ng/ml) 
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with anti-PAI-1 was capable to induce endothelial tube formation (Tab. 20, 
column10).  
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Table 20: Graphical representation of determination of tube lengths.  Representation of tube 
lengths formed by endothelial cells treated only with basal medium (1), with VEGF-A alone (2),  with 
100 ng/ml of ORM alone (3), with anti-PAI-1 (15 ng/ml) antibody alone (column4), with 100 ng/ml of 
ORM and VEGF-A simultaneously (5), with 15 ng/ml of anti-PAI-1 antibody and VEGF-A 
simultaneously (6), with ORM at 300 ng/ml and VEGF-A simultaneously (7), the application of ORM at 
300 ng/ml and anti-PAI-1 antibody in combination with VEGF-A (8), with 100 ng/ml of ORM, anti-PAI-1 
antibody and VEGF-A simultaneously (9), with 300 ng/ml of ORM and anti-PAI-1 antibody 
simultaneously (10). 
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5. Discussion 
This study provides the identification of new proteins/glycoproteins in the urine 
sample of patients with cancer of urinary bladder by combined application of 
proteomic technology such as 2-DE with subsequent mass spectrometric analyses, 
conventional protein research techniques such as immunoblotting, 
immunohistochemical studies on paraffin sections of bladder tissue, genetic 
approaches including gene silencing via siRNA technique and finally in-vitro 
mechanistic studies such as endothelial tube formations assay on collagen gel. In 
this study, the optimum conditions were established for appropriate separation of 
urinary proteins for the application of 2-DE technology on urine samples obtained 
from healthy persons and patients with bladder cancer of different stage as well as 
patients on follow-up. Going this way, two urinary proteins, ORM and ZAG, among 
other proteins found in the urine samples, which were not known to have a functional 
relation to the stages of bladder cancer and particularly to angiogenesis until now, 
were identified. This work was particularly focussed on the functions of ORM in 
endothelial cells. To explore the potential role of ORM in angiogenesis, genetic and 
mechanistical in-vitro studies such as endothelilal capillary formation assay were 
performed. 
5.1 The impact of 2-DE for characterization of urinary proteins 
 
In the last few years, new technologies were developed to identify proteins in body 
fluids including in urine. Among them a widely used method is the technique of the 
proteolytic digestion of the entire protein followed by LC coupled with MS/MS (Spahr 
et al., 2001). Surface-enhanced laser desorpsion/ionization (SELDI)-MS has been 
utilized to profile urinary proteins as an alternative high-throughput approach (Rogers 
et al., 2003; Schaub et al., 2004).  Among these techniques 2-DE with subsequent 
MS analysis is the more effective method for generating reproducible results in 
human proteome pattern and protein identification in body fluids including urine. This 
method has an advantage over the technique of proteolysis with subsequent MS/MS 
analysis due to a 2-DE which can show the relative protein expression profiles with 
molecular weights and pI. 
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5.2 Optimized separation of urinary proteins for performing of 2-DE as a 
 powerful tool for identification of urine proteins 
 
At the beginning of this study the first aim was to view complete protein pattern of 
urine samples and to predict the function of proteins which are present in urine. To 
address this aim this study focused on developing an effective sample preparation 
strategy for 2-DE. Additional sample preparation steps can improve the quality of 2-
DE images, but each additional step can results in the selective loss of protein 
species, which is discussed in several studies (Oh et al., 2004; Thongboonkerd and 
Malasit, 2005). To avoid loss of proteins, a sample preparation strategy was chosen 
as simple as possible. The principles of this preparation methods and of the 2-DE are 
described in section of material and methods. 
Until now, through extensive studies, a large number of protein spots have been 
identified, but many of them are charge-isoforms or specific breakdown products of 
abundant proteins such as albumin, fibrinogen, immunoglobulin, etc. However, 
whether the pattern of these breakdown products shows a disease specific 
composition or not is an interesting question but needs future analyses. In the 
literature there are, however, limited proteomic data on human urine due to low 
abundance of proteins and the complex nature of urine. The majority of proteins 
which are present in normal urine are originated from cytoplasm and have functional 
properties similar to plasma proteins (Anderson and Anderson, 2002; Oh et al., 
2004). The current certain limitations of proteomic analysis of the urine samples are: 
(i) the total protein amount is low, (ii) few proteins present in urine samples in a 
relatively high amount may lead to difficulties in identification of urinary proteins 
present only in very low concentrations and the locations of expressed proteins and 
(iii) urine contains high amounts of body filtrates such as water, salts, electrolytes 
and nitrogenous waste products which disturb 2-DE process. 
There are several studies describing methodes and techniques to achieve a higher 
protein concentration in urine samples such as dye- or solvent-precipitation, 
ultracentrifugation, lyophilisation and the removal of the proteins abundantly present 
in urine samples (Marshall and Williams, 1998; Pang et al., 2002; Thongboonkerd et 
al., 2004). To overcome these difficulties ultracentrifugation technique was applied 
using a centrifugal filter column to remove the salt, electrolytes, and small molecules 
(<10 kDa) and as well as to concentrate urine samples. Furthermore, the 
development of novel methodologies to better prepare the urine samples prior to their 
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use in 2-DE analyses was a necessary step. Although, considerable studies were 
published on mapping the human urinary proteome, most of these approaches 
require many steps for urine preparation prior to its use for 2-DE analyses such as 
precipitation methods, ultracentrifugation, removal of gylcosaminoglycans, dialysis 
steps, lyophilisation, gel filtration, even immunosubtraction of the most abundant 
proteins and/or other pre-fractionation tools (Thongboonkerd and Malasit, 2005). 
Recently, after publishing the data presented in this work, a novel method of solid 
phase based, selective adsorption of proteins for affinity ligands under controlled 
saturation conditions was described to increase the concentration of low-abundance 
proteins and to decrease the concentration of high-abundance proteins from same 
mixture in a single step (Thulasiraman et al., 2005). A further improvement in protein 
concentration/equalization technique was also recently described using beads coated 
with hexameric peptide ligand libraries (Castagna et al., 2005) and in that study 
additional 251 hidden urinary proteins has been reported. 
Under consideration of the methodological knowledge reported in literature at that 
time of the study presented in this work, several techniques were performed at the 
beginning of the experiments such as different protein precipitation methods (TCA, 
acetone, etc.) followed by testing the use of different rehydration buffers. We applied 
ultracentrifugation as a simple method to avoid loss of proteins and alteration in 
nature of urine. Efficiency of this sample preparation method used for urine samples 
was enough to obtain a reproducible and high-resolution human urine proteome 
pattern in 2-D gels. However, for further extended studies on urinary proteins, 
ultracentrifugation can be combined with the novel techniques mentioned above to 
improve the protein separation in 2-D gel. 
 
5.3 Urine proteomics enables the identification of proteins related to 
 bladder cancer 
 
Bladder cancer is diagnosed by cystoscopic evaluation, which is expensive and 
invasive. Urine cytology is the current non-invasive gold standard but it has low 
sensitivity (Konety and Getzenberg, 2001; Murphy et al., 1984). The search for 
bladder cancer biomarkers that could potentially replace cystoscopy as a diagnostic 
and surveillance tool has been complicated by the molecular heterogeneity of this 
disease. Numerous studies have focused on urine proteomics as a source for a 
potential biomarker. Vlahou (Vlahou et al., 2001) applied SELDI-TOF-MS to urine 
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samples to detect transitional cell bladder carcinoma (TCC). Up to date several 
urinary proteins, which are supposed to be related to bladder cancer, are described 
as a biomarker for bladder cancer such as urinary calreticulin (Kageyama et al., 
2004), calcium-binding protein psoriasin (Celis et al., 2004), nuclear matrix protein 
22, bladder tumor antigen, and telomerase (Ramakumar et al., 1999). 
After optimization of the techniques of protein preparation and 2-D gel 
electrophoresis on human urine samples we performed extensive analyses on a 
large number of urine samples of healthy persons, patient with bladder cancer, and 
patients on follow-up. Comparison of proteomic map of normal human urine with 
urine of patients with bladder cancer and patients on follow-up revealed few 
similarities but significant differences. The major differences were seen especially 
between urinary pattern of patients and healthy persons. The similarities concerned 
some protein spots at 55 kDa, which were later identified by mass spectrometric 
analyses as human serum albumin, and 66 kDa which were present in all urine 
samples. 
 
5.4 Novel protein spots in urine samples of patients with bladder cancer 
 using 2-DE may be of diagnostic relevance 
 
The comparison of the list of the proteins identified in this study with already 
published urinary protein databases (Castagna et al., 2005; Celis et al., 1996; Grover 
and Resnick, 1993; Oh et al., 2004; Pang et al., 2002; Pieper et al., 2004; 
Rasmussen et al., 1996; Thongboonkerd et al., 2002) revealed similarities regarding 
the detection of few proteins knowingly being present in the urine abundantly and 
deriving from blood plasma such as albumin, immunolglobulin, etc. Among a high 
number of protein spots being identified in silver staining of the 2-DE gel only a small 
part was also detectable in the CBB staining. These protein spots which have been 
identified to be either differentially up-regulated or only present in the urine samples 
of patients with bladder cancer were cut out from the gel and analyzed in mass 
spectrometric analyses. These analyses led to the reproducible identification and 
characterization of proteins such as ORM and ZAG. 
 
5.5 ORM is increased in urine samples of patients with bladder cancer  
 
Prior to the discussion of the impact of ORM in bladder cancer it is necessary to give 
a brief survey about ORM. It was firstly described in 1950 by Schmid (Schmid, 1950; 
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Schmid, 1953) and belongs to a group of acute phase proteins playing a role in the 
modulation of the immune response to stress, along with many other 
functions(Bennett and Schmid, 1980; Schmid, 1975). The relatively high 
concentration of ORM in the serum of healthy humans is known to rise two- to 
fivefold in response to different conditions such as acute infection, inflammatory and 
lymphoproliferative disorders and cancer (Schmid, 1975). 
The structure of ORM is well characterized and is composed of a polypeptide chain 
containing about 45 % carbohydrate including a large amount of fucosylic and sialic 
acid as mentioned above. Thus, its proposed immunomodulatory activities have been 
attributed to its glycosylation pattern, since the strongly fucosylated and sialylated 
ORM glycoforms have the ability to bind E-selectin and to inhibit complement 
activation (De Graaf et al., 1993). An induced expression of sialyl Lewis X (sLeX) on 
ORM during acute inflammation has been reported, leading to the speculation that it 
might influence the E- or P-selectin-mediated influx of sLeX-expressing leukocytes 
into inflamed areas. It has been suggested that an increased level of sLeX-
expressing ORM could have a feedback inhibitory effect on the extravasation of 
leukocytes, by competition for the E-selectin adhesion molecules (Lasky, 1992). So 
ORM is thought to modify the permeability of the vascular endothelium, possibly by 
interacting with the endothelial glycocalyx (Curry and Michel, 1980). Thus far it has 
been shown that ORM binds to the vascular endothelial cell surface and then causes 
transcytosis across the cell without passing the intercellular junction (Predescu et al., 
1998). 
It has been shown that the serum concentration of ORM is elevated in different types 
of cancers such as breast, lung and ovary cancer (Duche et al., 2000) leading to the 
assumption that ORM might be produced by cancer cells themselves. The present 
data here show a significantly increased ORM expression in urinary bladder tumors, 
particularly in the invasive stages of bladder cancer. Consequently, the detection of 
large amount of ORM proteins in the urine of bladder cancer patients, as 
demonstrated in this work, indicates an increased production and secretion of ORM. 
In the literature, a high number of studies report about ORM glycoform determination 
in serum diagnosis of different cancer types, such as colorectal (Hansen et al., 1987) 
and ovarian cancer (Dobryszycka W., 1992). However, only a few studies are 
available concerning the changes of ORM levels in the urine of patients. It has been 
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observed to be increased in urine of patients with acute inflammation (Pang et al., 
2002) and of normoalbuminuric type2 diabetic patients (Narita et al., 2004). 
After being identified in 2-DE of the urine analyses performed in this study also 
immunoblotting studies revealed an increased level of ORM in the urine samples of 
patients with bladder cancer and patients on follow-up. To my knowledge this is the 
first report showing that ORM is significantly increased in urine samples of patients 
with urinary bladder cancer, particularly in those with invasive tumor stages. The 
level of ORM has been observed to be increased in urine of patients with acute 
inflammation (Pang et al., 2002) and of normoalbuminuric type 2 diabetic patients 
(Narita et al., 2004). Correspondingly the results presented in 2-DE and 
immunoblotting studies here, the present immunohistochemical results suggest that, 
in addition to cancer cells, some tissue resident inflammatory cells and, interestingly, 
endothelial cells of angiogenicly activated blood vessels which are to find in close 
association to tumor tissue serve as source for this increase of ORM in the urine of 
bladder cancer patients. This would explain the highest increase in the mean protein 
amount of ORM at tumor stage pTa to pT1, which marks the switch from a non-
vascularized superficial tumor to a tumor type invading the lamina proria where the 
tumor cells get direct acces to blood vessels with activation of tumor 
neovascularization. Confirming the previous results presented by Soerensson et al. 
(Sorensson et al., 1999), the present findings show that human vascular endothelial 
cells produce ORM endogenously. Thus, the presence of ORM in endothelial cells 
activated by tumor angiogenesis or probably forming new tumor vessels as 
demonstrated here does not only reflect the endothelial-bound ORM but also ORM 
originating from endothelial cells. One of the essential characteristic phenomenons of 
angiogenically activated blood vessels is the abnormal vascular leakage or 
permeability (Hashizume et al., 2000). Indeed, ORM has been reported to modify the 
endothelial permeability, possibly by interacting with the endothelial glycocalyx (Curry 
and Michel, 1980; Predescu et al., 1998). Serum level of ORM is increased in 
inflammatory and lymphoproliferative disorders and cancer, such as breast, lung and 
ovary cancer (Duche et al., 2000; Schmid, 1975) which might be involved the 
modulation of vascular leakage. 
A further aspect of ORM structure is that ORM is a major carrier of sialyl Lewis X 
(sLeX), particularly during acute inflammation. This finding led to the speculation that 
via this carbohydrate moiety ORM might be able to bind to E- or P-selectin and might 
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influence the binding and rolling as well as extravasation of leukocytes into inflamed 
areas (Lasky, 1992). Similar to ORM, it was recently demonstrated that CEACAM1, a 
highly glycosylated cell adhesion molecule carrying sLeX and Lewis X residues and 
acting pro-angiogenic, is up-regulated in endothelial cells of new immature blood 
vessels of bladder cancer in early tumor stages (Oliveira-Ferrer et al., 2004). This 
structural similarity between both molecules, which are present in angiogenicly 
activated blood vessels, leads to the assumption that similar to CEACAM1 also ORM 
might be involved in the regulation of angiogenesis and tumor vascularization. To 
address the potential role of ORM in endothelial cell biology and angiogenesis, ORM 
overexpression and ORM gene silencing via siRNA in HDMECs were performed. 
After testing the efficiency of these experimental manipulations, genetically modified 
HDMECs were used in in vitro capillary formation assay (endothelial tube formation). 
 
5.6 Endothelial overexpression of ORM as well as endothelial stimulation by 
 ORM support the VEGF-induced endothelial tube formation 
 
Until now it has been shown that ORM binds to endothelial cell surface (Boncela et 
al., 2001) but it is so far unclear whether ORM plays a role in capillary 
morphogenesis provided by endothelial cells. The results presented here 
demonstrate clearly, that the majority of the overexpressed ORM in HDMECs is 
secreted into the supernatant. This finding suggests that probably ORM produced 
endogenously by endothelial cells might also be mainly secreted into the extra 
cellular space and thus, the ORM detected in cultured HDMECs and in endothelial 
cells of angiogenicly activated tumor blood vessels might mainly result in ORM 
binding on endothelial cell surface. Also data obtained by endothelial tube assay as 
presented here support this interpretation. While the use of HDMECs transfected for 
ORM in endothelial tube assay did not lead to significant differences in comparison to 
the wild type HDMECs when they were stimulated by VEGF, the simultaneous 
stimulation of wild type HDMECs by the supernatant of ORM overexpressing 
HDMECs and VEGF led to a significantly increased length and network of endothelial 
tubes in comparison to the stimulation of HDMECs by VEGF alone. This effect was 
partly reversed when endothelial cells on collagen gel were stimulated 
simultaneously with supernatant of ORM silenced HDMECs and VEGF indicating that 
the ORM-siRNA used here is to some extent effective in the in-vitro mechanistic 
studies. Since the supernatant of HDMECs transfected for ORM and ORM siRNA 
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simultaneously was not able to block endothelial tubes induced by application of 
VEGF completely one can assume that either the ORM-siRNA was not effective 
enough to block the endogenous production of ORM totally or there are other factors 
replacing the functional effects of ORM in endothelial tube formation. 
 
5.7 ORM interaction with PAI-1 influences the VEGF-induced endothelial  tube 
formation 
 
To gain more insight into the function of ORM in capillary morphogenesis, further in 
vitro endothelial tube formation studies were performed to investigate the role of the 
interaction between ORM and PAI-1. Recently it has been shown that ORM and PAI-
1 form a complex on the surface of endothelial cells which obviously influences the 
migration of endothelial cells (Boncela et al., 2001). These studies show that it is the 
active form of plasminogen activator inhibitor-1 (PAI-1) which constitutes the complex 
with ORM. The building of this complex stabilizes the active form of PAI-1 suggesting 
that ORM-PAI-1 complex would increase the inhibitory effect of PAI-1. The ORM-
PAI-1 co-localization was found in thymosin β4 (Tβ4)-activated but not in quiescent 
HUVECs (human umbilical cord vein endothelial cells). ORM may influence the 
adhesive properties of endothelial cells as well as their ability to generate plasmin 
(Boncela et al., 2001). The role of the urokinase type plasminogen activator (uPA) in 
angiogenesis is widely described in the literature (Andreasen et al., 2000; Binder et 
al., 2007; Boncela et al., 2001; Choong and Nadesapillai, 2003; Chorostowska-
Wynimko et al., 2004a; Chorostowska-Wynimko et al., 2004b). While the generation 
of plasmin from plasminogen by action of uPA or tPA is essential for the regulation of 
the activity of the coagulation system, it is well documented that uPA plays a crucial 
role in the remodelling of the extra cellular matrix including the vascular basement 
membrane normally underlying the endothelial cell layer and enclosing the pericytes 
in capillaries (Andreasen et al., 1997). A well construction of the basement 
membrane is of importance for the structural integrity of the vascular wall and also for 
migration activity of endothelial cells which is an essential step during the new 
formation of blood vessels by angiogenesis (Folkman and D'Amore, 1996). The pro-
angiogenic effects mediated by uPA are blocked by PAI-1 (Andreasen et al., 2000; 
Binder et al., 2007) which has been shown to interact with uPA and uPAR 
(Andreasen et al., 1997; Binder et al., 2007). This interaction shows a dual character 
as demonstrated in figure 50:  (i) The interaction of PAI-1 with uPA and uPAR leads 
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to the internalization of uPAR and its subsequent recycling and translocation to the 
membrane at the cellular tips which result in an increase of endothelial migration and 
angiogenic activity. (ii) The presence of ORM results in the building of a complex with 
PAI-1 at the endothelial cells surface which stabilizes the activity of PAI-1 leading to 
the blockage of uPAR internalization and recycling which consequently result in the 
suppression of endothelial migration and angiogenesis (Andreasen et al., 1997). 
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Figure 50: Important interactions within the uPAR-uPA-PAI-1 systems and the role of ORM. 
Normally uPA and uPAR interaction leads to internalization of uPAR and then recycling of uPAR 
resulting in activation of endothelial migration and angiogenesis (A). In the presence of ORM there is a 
complex of ORM and PAI-1 which stabilizes PAI-1 and suppresses then uPAR internalization and 
recycling. This results in inhibition of endothelial migration and angiogenesis (B). The additional 
application of anti-PAI-1 which blocks the complex building of PAI-1 and ORM increases the amount 
of free ORM acting with VEGF-A together proangiogenic and increases the endothelial migration and 
capillary formation, thereby, promotes angiogenesis (C). 
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However, the additional application of the anti-PAI-1 antibody as used here in 
endothelial tube formation assay blocks the building of ORM-PAI-1 complex with 
probably two consequences which increase the angiogenic activity of endothelial 
cells: (i) The blockage of complex building between ORM and PAI-1 results in 
enhanced uPAR internalization as described above, and (ii) the inhibition of ORM-
PAI-1-complex increases the amount of free ORM which obviously act pro-
angiogenicly when applied in combination with VEGF and enhances the VEGF-
induced capillary morphogenesis in-vitro. Thus, it is conceivable to postulate a role of 
the interaction between ORM and PAI-1 in the vascular morphogenesis. 
 
5.8 Zinc-alpha-2-glycoprotein is increased in urine samples of patients with 
 bladder cancer particularly in the invasive stages  
 
This study demonstrates for the first time that ZAG is detectable in an increased 
amount in the urine samples of patients with superficial as well as invasive tumors of 
urinary bladder. Interestingly, our immunohistochemical studies demonstrate that 
presence of ZAG at the luminal surface of normal transitional epithelium of urinary 
bladder switches to the basal side once a papillary tumor of the stage pTa is 
observed. Since in our studies the strongest immunostaining for ZAG was found in 
tumor cells invading the lamina propria of the bladder wall, we suggest a relationship 
between tumor invasion and ZAG, which needs further studies. In contrast to ORM, 
the strongest increase of ZAG is seen from the superficial tumor stage pT1 to the 
invasive tumor stage pT2, confirming our assumption that the ZAG enhancement is 
associated with the development of an invasive tumor and not with angiogenesis, 
whereas ORM increase seems to be related to angiogenic activation as discussed 
above. The exact mechanisms involved here need further studies on a higher 
number of tumor tissues and urine samples. ZAG is a soluble protein present in the 
serum, and has also been found in the cytoplasm of normal secretory epithelial cells, 
including those of breast, prostate, and liver, as well as in salivary, bronchial, 
gastrointestinal, and sweat glands (Burgi and Schmid, 1961; Tada et al., 1991). 
Increased expression of ZAG occurs in several types of malignant tumors (Brysk et 
al., 1997; ez-Itza et al., 1993) and the serum level of ZAG has been used as a cancer 
marker. Although the biological functions of ZAG remain largely unclarified, a 
lipidmobilizing factor purified from murine adenocarcinoma, MAC16, leading to 
cachexia, and from the urine of patients with cancer cachexia has been shown to be 
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identical to ZAG (Todorov et al., 1998). More recently, it was shown that 
overexpression of ZAG in adipocytes enhances tumor-associated cachexia in mice 
(Bing et al., 2004). 
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6 Conclusion 
 
In summary, the present results demonstrate that the combined use of proteomics 
technology with molecular cell biology approach and mechanistic in-vitro assays 
serve as a powerful tool to detect new proteins and factors related to disorder as 
shown here for human urinary bladder cancer and to clarify their role in the 
pathogenesis of the disorders. Specifically, the findings here show that ORM plays a 
clear role in the VEGF-induced capillary morphogenesis which might be of relevance 
for tumor vascularization and anti-angiogenic tumor therapy. 
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